

1 Title: Projecting vaccine demand and impact for emerging zoonotic pathogens

2

3 Authors: A Lerch<sup>1</sup>, QA ten Bosch<sup>2</sup>, M L'Azou Jackson<sup>3</sup>, AA Bettis<sup>4</sup>, M Bernuzzi<sup>3</sup>, GAV  
4 Murphy<sup>5</sup>, QM Tran<sup>1</sup>, JH Huber<sup>1</sup>, AS Siraj<sup>1</sup>, M Elliott<sup>1</sup>, C Hartlage<sup>1</sup>, K Koh<sup>1</sup>, K Strimbu<sup>1</sup>, M  
5 Walters<sup>1</sup>, TA Perkins<sup>1\*</sup>, SM Moore<sup>1\*</sup>

6

7 <sup>1</sup>Department of Biological Sciences and Eck Institute for Global Health, University of  
8 Notre Dame, Notre Dame, Indiana, USA

9

10 <sup>2</sup>Quantitative Veterinary Epidemiology, Wageningen University and Research,  
11 Wageningen, Netherlands

12

13 <sup>3</sup>Coalition for Epidemic Preparedness Innovations (CEPI), London, UK

14

15 <sup>4</sup>Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway

16

17 <sup>5</sup>Bill & Melinda Gates Foundation, Seattle, Washington, USA

18

19

20 \*Corresponding authors:

21 T Alex Perkins, [taperkins@nd.edu](mailto:taperkins@nd.edu)

22 Sean M Moore, [smoore15@nd.edu](mailto:smoore15@nd.edu)

23

## 24 **Abstract**

25

26 Despite large outbreaks in humans seeming improbable for a number of zoonotic pathogens,  
27 several pose a concern due to their epidemiological characteristics and evolutionary potential.  
28 To enable effective responses to these pathogens in the event that they undergo future  
29 emergence, the Coalition for Epidemic Preparedness Innovations is advancing the development  
30 of vaccines for several pathogens prioritized by the World Health Organization. A major  
31 challenge in this pursuit is anticipating demand for a vaccine stockpile to support outbreak  
32 response. We developed a modeling framework for outbreak response for emerging zoonoses  
33 under three reactive vaccination strategies. Annual vaccine regimen requirements for a  
34 population-wide strategy ranged from >670,000 (95% prediction interval: 0-3,630,000) for Lassa  
35 virus to 1,190,000 (95% PrI: 0-8,480,000) for Rift Valley fever virus, while the regimens required  
36 for ring vaccination or targeting healthcare workers (HCWs) were several orders of magnitude  
37 lower. For each pathogen and vaccination strategy, reactive vaccination typically prevented  
38 fewer than 10% of cases, because of their presently low  $R_0$  values. Targeting HCWs had a  
39 higher per-regimen impact than population-wide vaccination. Our framework provides a flexible  
40 methodology for estimating vaccine stockpile needs and the geographic distribution of demand  
41 under a range of outbreak response scenarios.

42

## 43 **Introduction**

44 Less than two years ago, SARS-CoV-2 was an unknown virus circulating in a zoonotic reservoir  
45 (Andersen et al. 2020). In the time since, it has caused a pandemic resulting in more than 4.6  
46 million deaths (WHO 2020). Theoretical work (Antia et al. 2003) predicts that frequent small-  
47 scale outbreaks in humans may provide opportunities for selection of more transmissible  
48 variants that facilitate emergence from the original reservoir. Indeed, virological studies indicate  
49 that a sequence of mutations acquired in this manner may offer a plausible explanation for the  
50 emergence of SARS-CoV in 2003 (Sheahan et al. 2008). More frequent spillover and more  
51 human-to-human transmission ensuing from those spillovers are expected to increase the  
52 probability that adaptations such as these arise and facilitate more widespread emergence  
53 (Morse et al. 2012). Because of this evolutionary potential, even zoonotic pathogens with limited  
54 human-to-human transmission—as defined by a basic reproduction number,  $R_0$ , below 1—are  
55 viewed as a concern. The status quo of investing in the development of diagnostics,  
56 therapeutics, and vaccines only in reaction to emerging disease threats has made the world  
57 dangerously vulnerable to pandemics (Røttingen et al. 2017; Excler et al. 2021).


58 To preempt future public health emergencies arising from emerging zoonotic diseases, the  
59 World Health Organization (WHO) developed a research and development blueprint for action  
60 to prevent epidemics (WHO 2016). This R&D Blueprint prioritizes and regularly updates a list of  
61 pathogens for development of diagnostics, therapeutics, and vaccines  
62 ([https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)  
63 [emergency-contexts](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)). The Coalition for Epidemic Preparedness Innovations (CEPI) was  
64 launched in 2017 to accelerate the development of vaccines against emerging infectious  
65 diseases and to enable equitable access to these vaccines for people during outbreaks  
66 (Gouglas et al. 2019; Bernasconi et al. 2020; Huneycutt et al. 2020). The first call for proposals

67 from CEPI was on developing vaccines for Lassa virus (LASV), MERS coronavirus (MERS-  
68 CoV), and Nipah virus (NiV). Soon after, it added Rift Valley fever virus (RVFV) and  
69 chikungunya virus (CHIKV) to its portfolio. As of early 2021, CEPI was supporting development  
70 of a total of 19 different vaccine candidates for these five diseases, in addition to other efforts  
71 related to Ebola, COVID-19, and “disease X” (CEPI 2018).

72 In anticipation of vaccine candidates for these diseases progressing through safety and efficacy  
73 trials and towards implementation, there is a need to understand future potential vaccine  
74 demand (Røttingen et al. 2017). Even though these vaccines are not yet available for public  
75 health use, understanding demand at an early stage is important to inform fundraising and  
76 planning efforts in support of the manufacturing and distribution infrastructure that will be  
77 required for their implementation (Excler et al. 2021). Following the development of a new  
78 vaccine, manufacturing capacities are typically the first limiting factor for vaccine supply, which  
79 raises allocation and prioritization decisions to protect people at higher risk of infection and  
80 clinical disease (Medlock and Galvani 2009; Bubar et al. 2021). Appropriate planning of vaccine  
81 stockpiles to support vaccine demand is important to minimize the extent to which difficult  
82 decisions about vaccine prioritization must be made once a vaccine becomes available for use.  
83 At the same time, overestimating vaccine stockpile needs could result in doses expiring and  
84 resources that could have gone to other needs being wasted.

85 To improve capabilities to plan vaccine stockpiles for emerging zoonotic pathogens, we  
86 developed a modeling framework to quantify the vaccine stockpile size needed to meet demand  
87 for outbreak response and applied it to LASV, MERS-CoV, NiV, and RVFV (Figure 1). Each of  
88 these pathogens is zoonotic, with the majority of human cases believed to result from spillover  
89 transmission from non-human hosts accompanied by self-limiting, human-to-human  
90 transmission (Linthicum, Britch, and Anyamba 2016; Cauchemez et al. 2016; Siddle et al. 2018;  
91 Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et  
92 al. 2019). Our model is driven by geographically and seasonally realistic patterns of spillover for  
93 each pathogen, with each spillover event having the potential to spark an outbreak that we  
94 simulated stochastically with a branching process model. Outbreak response with reactive  
95 vaccination was triggered in our model whenever a threshold number of cases was exceeded  
96 within a certain space-time window. We quantified the number of vaccine regimens required  
97 (where the number of regimens equals the number of individuals vaccinated) under three  
98 different approaches to reactive vaccination: 1) population-wide within the same geographic  
99 area as the outbreak, 2) targeted on healthcare workers (HCWs) within that area, or 3) targeted  
100 on a ring of contacts around each index case. Using vaccines modeled after target product  
101 profiles for each pathogen (WHO 2017c, 2017b, 2017a, 2019), we also quantified the impact of  
102 reactive vaccination under a range of scenarios about deployment timing, coverage, per  
103 exposure protection (PEP) from vaccination, and several epidemiological parameters.

104



106 **Figure 1. Overview of this study.** We considered four emerging zoonoses prioritized by the WHO R&D  
 107 Blueprint and CEPI. For each, we modeled spillover, human-to-human transmission, and reactive  
 108 vaccination. We quantified the vaccine stockpile necessary to meet demands of reactive vaccination  
 109 under three scenarios: vaccinating an entire population within the same geographic area as a detected  
 110 outbreak, vaccinating healthcare workers within that geographic area, or vaccinating contacts associated  
 111 with each spillover case. **Lassa fever** is caused by LASV, a virus that circulates in rodents in West Africa  
 112 and has resulted in thousands of cases and deaths in recent years (Mylne et al. 2015; Roberts 2018).  
 113 **Nipah** is caused by NiV, a virus that circulates in fruit bats that can be found throughout tropical and  
 114 subtropical Asia (Yob et al. 2001; Luby et al. 2009), but documented spillover to humans has been mainly  
 115 limited to India, Bangladesh, and Malaysia (Pulliam et al. 2012; Girish Kumar et al. 2019; Nikolay, Salje,  
 116 Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019). **MERS** is  
 117 caused by MERS-CoV, a coronavirus that probably originated in bats (Anthony et al. 2017), and is known  
 118 to circulate among domestic camel populations in the Middle East and parts of eastern and northern  
 119 Africa, resulting in spillover from camels to humans (Müller et al. 2015; Dudas et al. 2018; Hui et al.  
 120 2018). Human-to-human transmission has been reported in nosocomial settings for three of these  
 121 pathogens (Fisher-Hoch et al. 1995; Park et al. 2016; Nikolay, Salje, Hossain, Khan, Sazzad, Rahman,  
 122 Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019), although only MERS was reported in large  
 123 hospital outbreaks (Assiri, McGeer, et al. 2013; Park et al. 2016). The evidence for community  
 124 transmission of these viruses is more limited (Siddle et al. 2018; Hui et al. 2018; Nikolay, Salje, Hossain,  
 125 Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019). **Rift Valley fever** is  
 126 caused by RVFV, a mosquito-transmitted virus infecting ruminant livestock species in Africa, the Arabian  
 127 Peninsula, and the Indian Ocean islands (Pepin et al. 2010; Bron et al. 2021; Gerken et al. 2021). RVF  
 128 outbreaks have been associated with heavy rainfall in eastern and southern Africa (Anyamba et al. 2009,  
 129 2010), but transmission can also occur outside of these epizootic events (Linthicum, Britch, and Anyamba  
 130 2016). Humans can be infected via direct contact with infected animals or via mosquito bite, but are  
 131 believed to be dead-end hosts (Al-Hamdan et al. 2015).

132  
 133

## 134 **Methods**

135

### 136 *Epidemiological data*

137

138 For each of the pathogens, we collated epidemiological data through the end of 2020 from  
139 multiple sources, including WHO outbreak reports (e.g., (CSR n.d.)), ProMED reports  
140 (<https://promedmail.org>), country-level reports (<https://www.moh.gov.sa>, <https://ncdc.gov.ng>),  
141 and a literature search. A detailed overview of the source of epidemiological data for each  
142 pathogen can be found in the Supplementary Table S1.

143

### 144 *Spillover simulation*

145 Given extensive spatial heterogeneity of incidence, we collated epidemiological data at the first  
146 administrative level (adm1) in each country—e.g., province or state—within the study region for  
147 each pathogen. The primary epidemiological data used to inform spillover rates was the annual  
148 incidence of reported cases of each pathogen at the adm1 level (Table S1). Where possible,  
149 case data was categorized into cases of documented or suspected human-to-human  
150 transmission, documented or suspected spillover cases, and cases of unknown origin. The  
151 geographic coverage of our analysis for each pathogen was determined by the geographic  
152 distribution of spillover cases in the literature. All countries with at least one documented  
153 spillover case were included in our analysis. We excluded countries with imported cases but no  
154 spillover from a zoonotic source (e.g., South Korea for MERS-CoV).

155 Spillover rates were estimated using a generalized linear mixed model (GLMM) with a zero-  
156 inflated negative binomial distribution to capture overdispersion in the annual distribution of  
157 spillover cases within an adm1. Spillover cases were defined as documented spillover cases,  
158 suspected spillover cases, or cases of unknown origin; thereby excluding any cases of  
159 documented or suspected human-to-human transmission. Year, country, and adm1 were  
160 treated as random effects, with the adm1 variable nested within the country variable. Year was  
161 also included as a random effect for the zero-inflated portion of the model. Model fitting was  
162 conducted using the glmmTMB package in R (Brooks et al. 2017). This default model did not  
163 converge for NiV; therefore, for NiV we used the GLMM model without the random effect by  
164 year in the zero-inflated portion of the model to enable convergence. Then, for each pathogen,  
165 we simulated annual spillover cases for each year and adm1 by taking draws (1,000 replicates)  
166 from a zero-inflated negative binomial distribution using the estimated parameters from the  
167 appropriate GLMM fit. We randomly sampled 1,000 of these simulated spillovers from the last  
168 five years as inputs to the outbreak simulation model.

169

170 To account for the seasonality of spillover, we fitted a beta distribution to the timing of spillover  
171 cases within a year (daily for MERS, weekly for Lassa fever, monthly for Nipah and RVF) and  
172 simulated the timing of each spillover case as a random draw from that distribution (Table 1). To  
173 account for spatial clustering of cases below the adm1 level, we associated each simulated  
174 case with a catchment area. We did so according to probabilities proportional to catchment area  
175 population. Catchment areas were defined by second administrative level (adm2) or hospitals  
176 aggregated within 10 km, which would be consistent with an assumption that cases that seek

177 treatment for the relatively severe symptoms of these diseases do so at larger hospitals.  
178 Hospital location data for sub-Saharan Africa used in the analysis of LASV was obtained from  
179 (Maina et al. 2019), and hospital location data outside of sub-Saharan Africa was obtained from  
180 <https://www.healthsites.io> (Saameli et al. 2018). The primary set of findings we reported are  
181 based on a set of 1,570 catchment areas for LASV, 767 for MERS-CoV, 5,076 for NiV and  
182 2,126 for RVFV, which differ because of the different geography of each pathogen. We  
183 examined the sensitivity of our results to the definition of a catchment area by rerunning the  
184 analyses with either adm1 catchment areas or all hospitals within an adm1 as distinct catchment  
185 areas. The results of these analyses are presented in the Supplement (SI Text).


186

### 187 *Outbreak simulation*

188

189 To simulate incidence attributable to human-to-human transmission, we considered each  
190 spillover case as a potential index case for an outbreak. A schematic overview of both the  
191 spillover and outbreak simulation models, including outbreak response, is provided in Figure 2.  
192 Human-to-human transmission was simulated stochastically using a branching process model.  
193 For each primary case, a certain number of secondary cases was drawn either from a Poisson  
194 distribution (for Lassa fever and RVF) with  $\lambda = R_0$ , or from a negative binomial distribution (for  
195 MERS and Nipah) with  $\mu = R_0$  and a dispersion parameter,  $k$ . A Poisson distribution was used  
196 for Lassa fever and RVF, because both have an estimated  $R_0 < 0.1$  and no available estimate of  
197 overdispersion. We used a negative binomial distribution for MERS and Nipah, because  
198 secondary cases for these diseases are known to be overdispersed, with a majority of human-  
199 to-human transmission arising from a small minority of primary cases (Cauchemez et al. 2016;  
200 Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, and  
201 Others 2019).

202



<sup>S</sup> Model inputs that were varied as part of our sensitivity analysis

204 **Figure 2. Schematic of the spillover simulation and outbreak simulation models.** The spillover  
 205 simulation model estimates the magnitude and timing (seasonality) of the spillover rate for each  
 206 catchment area from the historical distribution of reported spillovers in the catchment area. These  
 207 estimated spillover rates are input into our outbreak model for each catchment area (as identified by the  
 208 bolded model input), which used a branching process model to simulate human-to-human transmission.  
 209 An outbreak response was triggered within a catchment area if the number of reported cases exceeded a  
 210 predetermined number within a 28d time window (outbreak threshold size). Outbreak model inputs with a  
 211 superscript S were varied as part of our sensitivity analysis.

212  
 213 We estimated  $R_0$  and variability therein differently for each pathogen. For LASV, we estimated  
 214 an  $R_0$  for nosocomial transmission by fitting a simple branching process model to observed  
 215 outbreak sizes from (Lo Iacono et al. 2015) using the optimize function in R and assuming a  
 216 Poisson offspring distribution (Farrington, Kanaan, and Gay 2003). The resulting estimate of  $R_0$   
 217 for LASV was 0.063 (95% confidence interval [CI]: 0.04 - 0.08) (Table 1). For MERS-CoV, we  
 218 compiled estimates of  $R_0$  from multiple studies analyzing data from MERS outbreaks  
 219 (Cauchemez et al. 2014; Breban, Riou, and Fontanet 2013; Poletto et al. 2014; Chowell et al.  
 220 2014; Cauchemez et al. 2016; Kucharski and Althaus 2015) and described variability in those  
 221 estimates with a gamma distribution, which resulted in a median  $R_0$  of 0.583 (90% CI: 0.305 -  
 222 0.993). The dispersion parameter estimate,  $k=0.26$ , for MERS-CoV was obtained from  
 223 (Kucharski and Althaus 2015). For NiV, we estimated  $R_0$  and its variability from detailed  
 224 epidemiological investigations of Nipah outbreaks in Bangladesh that estimated person-to-  
 225 person chains of NiV transmission (Nikolay 2019). Using data from these studies on the number

226 of secondary infections per primary infection and the size of each transmission cluster, we  
 227 obtained maximum-likelihood estimates of  $R_0$  (0.33, 95% CI: 0.21 - 0.52) and  $k$  (0.048, 95% CI:  
 228 0.031 - 0.074), which were consistent with a branching process with a negative binomial  
 229 offspring distribution. For RVFV, we assumed  $R_0=0$ , and considered  $R_0=0.01$  for sensitivity  
 230 analysis only, as no human-to-human transmission has been definitively documented to date  
 231 (Al-Hamdan et al. 2015).

232 The timing of incubation and infectious periods were then simulated subsequently based on  
 233 gamma distributions of those periods that we estimated by fitting a model to reconcile variability  
 234 in previously published estimates (Table 1). As no human-to-human transmission is known for  
 235 RVFV, we assumed for the sensitivity analysis a fixed duration for the infectious period of 7  
 236 days that is consistent with the duration of detectable viremia after onset of symptoms (Bird et  
 237 al. 2009). For all pathogens, the infection date of secondary cases was simulated as a draw  
 238 from a uniform distribution over the infectious period of the primary case. Each secondary case  
 239 was assigned to the same catchment area as the associated index case. A detailed overview of  
 240 the source for each parameter of each pathogen can be found in the Supplementary Table S1.

241

242 **Table 1. Overview of parameter estimates.** Incubation period and infectious period are  
 243 defined in units of days, and parameters for seasonality refer to week of the year.

Parameter	LASV	MERS-CoV	NiV	RVFV
Seasonality				
- Peak (wk)	31.1	23.3	27.3	23.2
- SD (wk)	6.2	13.6	6.4	12.7
Incubation period				
- Mean (d)	12.05	5.56	9.87	2.88
- SD (d)	3.62	0.77	0.84	1.95
Infectious period				
- Mean (d)	11.31	13.5	6.49	7 <sup>1</sup>
- SD (d)	8.29	2.61	0.26	-
$R_0$				
- Mean	0.063 (0.05, 0.08)	0.58 (0.31, 0.99)	0.325 (0.21, 0.52)	0 (0.01)
- Dispersion	-	1.42	0.048	-

244 <sup>1</sup> Fixed value used for sensitivity analysis only.

245

### 246 *Vaccine campaign simulation*

247

248 Three different reactive vaccination strategies were evaluated: 1) vaccinating a portion of the  
 249 general population in a given catchment area; 2) specifically targeting the HCWs in that  
 250 catchment area; or 3) adopting a ring vaccination strategy where the local population  
 251 surrounding each index case are targeted for vaccination. These strategies were chosen as  
 252 they represent three of the most frequently deployed outbreak response strategies. For each  
 253 strategy, baseline vaccination campaign parameter values (and parameter ranges for the  
 254 sensitivity analysis) were based on vaccine target product profiles for each pathogen (WHO



255 2017c, 2017b, 2017a, 2019), or chosen in consultation with CEPI and subject-matter experts for  
256 each pathogen (Table 2).

257  
258 To estimate the impact of vaccination, we simulated each outbreak response relative to a  
259 counterfactual simulation in which there was no outbreak response. Vaccination impact was  
260 defined as the number of cases averted via vaccination and calculated by taking the difference  
261 between the number of cases in the vaccination and no-vaccination scenarios. In our baseline  
262 scenario, an outbreak response within a single catchment area was triggered once ten cases for  
263 Lassa fever and MERS or three cases for Nipah and RVF were detected within a four-week  
264 window (Table 2). These outbreak response thresholds were chosen through discussion with  
265 CEPI and pathogen experts, and do not necessarily match the different outbreak definitions  
266 currently used by WHO or individual countries. The vaccination start date was calculated by  
267 adding a delay to the outbreak response date. To simplify vaccine uptake in our model, we  
268 assumed that each target population was immunized on a single day. Multi-day vaccination  
269 campaigns would likely reduce the impact of outbreak response relative to our estimates, but  
270 this impact would be less severe than a comparable delay in protection following vaccination  
271 because at least a portion of the population would be protected at the beginning of the  
272 campaign. Therefore, our analysis of the sensitivity of vaccination impact to a delay in protection  
273 following vaccination could be considered an upper bound on the sensitivity to extending the  
274 vaccine administration period for a given round of vaccination. In the case of a 2-dose vaccine,  
275 an additional delay of 28 days was assumed between administration of the first and second  
276 doses.

277  
278 For the general population vaccination strategy, HCWs were treated as part of the general  
279 population and were vaccinated with the same probability as the general population. For the  
280 HCW vaccination strategy, non-HCWs were not vaccinated, except for a hybrid strategy tested  
281 as part of our sensitivity analysis, where 20% of the general population was vaccinated versus  
282 80% of HCWs (Table 2). For the ring vaccination strategy, we calculated the number of index  
283 cases that would arise after the reactive vaccination campaign had started and assumed that 90  
284 vaccine regimens would be needed to vaccinate a ring of individuals around each index case  
285 based on estimates from ring vaccination campaigns during recent Ebola and cholera outbreaks  
286 (Ali et al. 2016; Henao-Restrepo et al. 2017). For the ring vaccination strategy we only  
287 estimated the number of vaccine regimens that would be required and did not attempt to  
288 estimate the impact of vaccination, because our model was designed to simulate a single  
289 vaccine campaign and not the periodic deployment as required by a ring vaccination strategy.

290  
291 Once a vaccination campaign was completed and the delay between vaccination and protective  
292 immunity had elapsed, vaccination in the general population removed spillover cases with a  
293 probability equal to vaccination coverage in the general population multiplied by per exposure  
294 protection (PEP). Vaccination of the general population also removed patient-to-HCW  
295 nosocomial cases with probability equal to vaccination coverage in HCWs multiplied by PEP.  
296 Vaccination of HCWs had no impact on spillover cases, but it removed nosocomial cases with  
297 probability equal to vaccination coverage in HCWs multiplied by PEP. PEP depended on  
298 whether a sufficient amount of time since vaccination had elapsed and, in the event of a two-

299 dose vaccine, whether an individual had received one dose or two doses at the time of  
 300 exposure (Table 2). Cases downstream in a transmission chain from a case averted by  
 301 vaccination were also averted.

302  
 303 **Table 2. Overview of simulation scenarios.** Parameter values for the baseline reactive  
 304 vaccination scenario for each pathogen. Outbreak response threshold cases and threshold  
 305 window refer to the number of cases that need to occur within a certain time window to trigger  
 306 an outbreak response. Parameter values in parentheses are alternative values used as a part of  
 307 the sensitivity analysis.

Parameter	LASV, MERS-CoV	NiV, RVFV
Outbreak response		
- Threshold cases	10 (5)	3 (1, 5)
- Threshold window	28d	28d
- Delay	28d (7, 120)	28d (7, 120)
Vaccination		
- Coverage HCW <sup>1</sup>		70% (80, 50, 90)
- Coverage population		70% (20, 50, 90)
- Delay between dose		28d
- Regimens per index case (ring vaccination only)		90
Protection		
- Single dose		70% (50%, 90%)
- Two dose 1st		35% (25%, 45%)
- Two dose 2nd		70% (50%, 90%)
- Delay		7d (14)

308 <sup>1</sup> Excluded for RVFV as no nosocomial transmission has been documented.

309  
 310 *Vaccine demand calculation*

311  
 312 To quantify the number of regimens required to meet the demands of a given outbreak  
 313 response strategy, we estimated the number of healthcare workers and overall population  
 314 associated with each catchment area where an outbreak occurred. The overall population per  
 315 catchment area was estimated based on WorldPop data from 2015 (Tatem 2017). For  
 316 healthcare workers, we took the national-level numbers of healthcare workers and distributed  
 317 them proportional to the population associated with each catchment area (Ref (WHO n.d.)).

318  
 319 *Graphical user interface*

320  
 321 A generalized implementation of the model is provided as a graphical user interface (GUI) at  
 322 <http://eidvaccinedemand.crc.nd.edu>. In the generalized implementation, a few adjustments were  
 323 made to allow for more flexible application of the model and to make computing time more  
 324 acceptable for an interactive web tool. First, annual spillovers are drawn from a negative  
 325 binomial distribution and then distributed across the catchment areas with a multinomial  
 326 distribution proportional to the probability that spillovers occur in these catchment areas.  
 327 Second, the population in the catchment areas were defined by a negative binomial distribution

328 so that specific geographies did not need to be reproduced. The default parameters for the GUI  
329 of each pathogen were obtained by fitting the corresponding distribution function to the  
330 estimated spillover and population data from this study. The source code for the GUI is provided  
331 at [https://github.com/lerch-a/CEPI\\_VaccineCampaignGUI](https://github.com/lerch-a/CEPI_VaccineCampaignGUI).

332

## 333 **Results**

334

### 335 *Spillover cases and human-to-human transmission*

336

337 The median annual number of spillover cases was 6 (95% prediction interval: 0-190) for Nipah,  
338 114 (95% PrI: 48-266) for MERS, 185 (95% PrI: 8-13,134) for RVF, and 417 (95% PrI: 142-  
339 1,837) for Lassa fever (Figure 3A). Simulated variability in the annual number of spillover cases  
340 matched the cumulative distribution of observed spillover cases for each pathogen (SI Figures  
341 S1B-S4B). Spillover rates for each pathogen varied both seasonally (SI Figures S1A-S4A) and  
342 geographically (Figure 4A). Spillover cases of Lassa fever were concentrated in Sierra Leone,  
343 Liberia, and Nigeria, although a few spillover cases occurred in other western African countries.  
344 Spillover of RVF to humans was widespread in South Africa, Madagascar, eastern Africa and  
345 the Arabian Peninsula, with frequent spillover cases occurring in several western and northern  
346 Africa countries as well. The majority of MERS spillover cases occurred in Saudi Arabia, and the  
347 majority of Nipah spillover cases occurred in Bangladesh, with additional spillover events in  
348 India and Malaysia.

349

350 The number of cases arising from human-to-human transmission depended on both the  
351 spillover rate and  $R_0$  (Figure 3A). Under our default parameter assumptions, there was no  
352 human-to-human RVFV transmission, but in the absence of vaccination the median annual  
353 number of human-to-human cases following spillover was 2 (95% PrI: 0-82) for Nipah, 29 (95%  
354 PrI: 11-143) for Lassa fever, and 161 (95% PrI: 46-407) for MERS (see Figure 5 for an example  
355 of the transmission chains for one catchment area).


356

### 357 *Estimates of vaccine demand*

358


359 In our analysis, a median of 0 (95% PrI: 0-8) Nipah reactive vaccination campaigns were  
360 triggered annually, compared to 4 (95% PrI: 0-11) MERS campaigns, 5 (95% PrI: 0-20) RVF  
361 campaigns, and 0 (95% PrI: 0-20) Lassa fever campaigns (Figure 3B). The locations of reactive  
362 vaccination campaigns broadly followed the geographic distribution of spillovers for each  
363 pathogen, although Lassa fever spillovers in Guinea, Benin, Togo, and western Nigeria were  
364 rarely reported frequently enough to trigger a response in our simulations (Figure 4B). The  
365 number of reactive vaccination campaigns that were triggered, and the timing of those  
366 campaigns, was strongly influenced by the seasonal pattern of pathogen spillover (SI Figures  
367 S1-S4).

368




370 **Figure 3. Simulated annual cases and reactive vaccination impacts.** (A) Annual number of spillover,  
371 human-to-human (H2H), and total cases for each pathogen across the entire study region (in the absence of vaccination). (B) Violin plot (including box plot representing the median, IQR, and 95% CI) of the  
372 annual number of vaccine campaigns triggered due to the outbreak threshold being exceeded across  
373 1,000 simulations for each pathogen. (C) Number of vaccine regimens required per year for reactive  
374 vaccination under our baseline scenario under three alternative assumptions about the target of  
375 vaccination campaigns. (D) Violin plot (including box plot representing the median, IQR, and 95% CI) of  
376 annual number of cases averted by reactive vaccination campaigns across 1,000 simulations for each  
377 pathogen. All y-axes are log<sub>10</sub> scaled.

378  
379  
380  
381



384 **Figure 4. Geographic distribution of predicted spillover cases and reactive vaccination**  
385 **campaigns.** (A) Geographic distribution of the expected annual number of spillover cases for each  
386 pathogen. (B) The annual probability that a campaign will be triggered in each catchment area based on  
387 1,000 simulations (probability is represented by size of the circle in each catchment area).  
388

389



390

391 **Figure 5. Timing of spillover and nosocomial cases in a single realization.** (Bottom) Individual cases

392 are visualized as thick horizontal lines, with observed cases in yellow/orange and averted cases in gray

393 (yellow and light gray indicate incubation time, orange and dark gray indicate infectious time). Unrelated

394 transmission trees are separated by thin horizontal gray lines. The dashed vertical line indicates the date

395 the outbreak threshold was reached. Triangles indicate vaccination date and diamonds indicate protection

396 date. (Top) Number of observed (orange) and averted (gray) cases per week.

397

398 For all four pathogens, there was a wide range in the number of vaccine regimens required in a

399 typical year due to the dependence of vaccine demand on the spatiotemporal clustering of

400 spillover cases required to trigger an outbreak response. The largest annual vaccine demand

401 was for RVFV, with a median of 1,191,741 (95% PrI: 0-8,480,275) vaccine regimens required to

402 target the general population under our baseline outbreak response scenario (Figure 3C). The  
403 median number of vaccine regimens for MERS-CoV was 870,045 (95% PrI: 0-2,843,407). The  
404 median number of vaccine regimens needed for NiV and LASV was zero, implying that an  
405 outbreak response was triggered less than 50% of the time. However, the mean number of  
406 vaccine regimens was 673,167 (95% PrI: 0-3,629,052) for LASV and 1,450,177 (95% PrI: 0-  
407 12,240,814) for NiV (Figure 3C). The number of vaccine regimens required to conduct a ring  
408 vaccination strategy or to cover healthcare workers as a part of an outbreak response was  
409 typically several orders of magnitude lower than the number required to cover the general  
410 population (Figure 3C). The median number of MERS-CoV vaccine regimens required to cover  
411 healthcare workers was 6,786 (95% PrI: 0-22,086). A median of 1,540 (95% PrI: 0-62,320)  
412 vaccine regimens were needed among healthcare/veterinary workers for RVFV outbreak  
413 response, 0 (mean: 1,144; 95% PrI: 0-6,485) were required for LASV, and 0 (mean: 2,330; 95%  
414 PrI: 0-15,833) for NiV. The median number of vaccine regimens required for ring vaccination  
415 was 4,860 (95% PrI: 0-21,429) for MERS-CoV, 12,150 (95% PrI: 0-1,175,758) for RVFV, 0  
416 (mean: 13,774; 95% PrI: 0-108,056) for LASV, and 0 (mean: 2,605; 95% PrI: 0-21,641) for NiV.

417

#### 418 *Impact of outbreak response*

419

420 The estimated impact of reactive vaccination as an outbreak response tool was generally low for  
421 all four pathogens. Vaccinating 70% of the general population in response to an outbreak with a  
422 single-dose vaccine prevented an annual median of 43 (95% PrI: 0-5,853) RVF cases, 6 (95%  
423 PrI: 0-83) MERS cases, 0 (95% PrI: 0-90) Nipah cases, and 0 (95% PrI: 0-357) cases of Lassa  
424 fever (Figure 3D). These vaccine impacts correspond to 0.69 (95% PrI: 0-2.92) cases averted  
425 per 100,000 vaccine regimens administered for MERS, 3.61 (95% PrI: 0-69.02) for RVF, 0 (95%  
426 PrI: 0-9.84) for Lassa fever, and 0 (95% PrI: 0-0.74) for Nipah. Vaccinating only healthcare  
427 workers typically had a smaller total impact than vaccinating the general population at the same  
428 coverage level, because there was no protection against spillover in the general population, but  
429 a larger per-regimen impact due to the lower number of regimens required. Vaccinating 70% of  
430 HCWs prevented an annual median of 4 (95% PrI: 0-77) MERS cases, corresponding to 58.9  
431 (95% PrI: 0-348.6) cases averted per 100,000 vaccine regimens in HCWs. Vaccinating HCWs  
432 averted 0 (95% PrI: 0-46) Lassa fever cases and 0 (95% PrI: 0-48) Nipah cases, corresponding  
433 to 0 (95% PrI: 0-710.4) and (95% PrI: 0-303.5) cases averted per 100,000 HCW vaccine  
434 regimens respectively (we did not explore vaccinating HCWs against RVFV due to the lack of  
435 any documented nosocomial transmission).

436

#### 437 *Sensitivity analysis*

438

439 The number of total cases increased with higher  $R_0$  values for each pathogen, with the largest  
440 sensitivity observed for MERS-CoV, because its higher value of  $R_0$  was close to one (Figure  
441 S16). There was also a large increase in the number of vaccine regimens required to vaccinate  
442 either the general population or HCWs for MERS-CoV at the higher  $R_0$  value, but the impact of  
443  $R_0$  on the required number of vaccine regimens was minimal for the other pathogens (Figures  
444 S17-S18). As a result, there were minimal differences in the impact of vaccination under higher  
445 or lower  $R_0$  values for LASV, NiV, or RVFV (Figures S19-S22). Vaccination averted both a

446 greater magnitude and a higher fraction of MERS cases as  $R_0$  increased (Figures S19-S20). In  
447 addition, the number of MERS cases averted per vaccine regimen administered to the general  
448 population or to HCWs also increased as  $R_0$  increased (Figures S21-S22).


449  
450 Lowering the outbreak threshold (from 10 to 5 cases within a 28 day window for MERS-CoV and  
451 LASV, and from 3 to 1 cases for NiV and RVFV) increased both the number of vaccine  
452 regimens needed for outbreak response and the number of cases averted. With the lower  
453 outbreak threshold, the projected demand for MERS-CoV vaccine regimens was 2,351,059  
454 (95% PrI: 492,028-5,872,847), a 170% increase, while the median number of cases averted  
455 was 19 (95% PrI: 0-162), a 217% increase compared to the baseline. The required number of  
456 vaccine regimens for RVFV increased to 4,793,351 (95% PrI: 659,297-14,157,197), a 302%  
457 increase, while the median number of RVF cases averted was 66 (95% PrI: 0-6,066), a 53%  
458 increase. The median number of vaccine regimens for LASV increased from 0 to 756,273 (95%  
459 PrI: 0-6,644,995), and the median number of Lassa fever cases averted increased from 0 to 15  
460 (95% PrI: 0-534). The median number of vaccine regimens for NiV increased from 0 to  
461 3,501,587 (95% PrI: 0-54,814,275), but the median number of cases averted remained 0 (95%  
462 PrI: 0-119). When the outbreak threshold was increased to 5 cases for RVF, the required  
463 number of vaccine regimens decreased by 50% to 594,894 (95% PrI: 0-7,493,183). The number  
464 of RVF cases averted via vaccination decreased to 26 (95% PrI: 0-5,735), which was 41% fewer  
465 cases averted compared with an outbreak threshold of 3 cases.

466  
467 Decreasing the time delay between the outbreak threshold being reached and the start of the  
468 vaccination campaign tended to increase the number of cases averted, while increasing the  
469 delay reduced the number of cases averted (Figure 6). For MERS-CoV, reducing the time delay  
470 from 28 to 7 days increased the median number of cases averted from 6 (95% PrI: 0-83) to 14  
471 (95% PrI: 0-112), while increasing the delay to 120 days reduced the number of cases averted  
472 to 0 (95% PrI: 0-38).

473  
474 Increasing or decreasing the percentage of the population that was targeted during reactive  
475 vaccination campaigns also led to corresponding increases or decreases in the number of  
476 cases averted (Figure 6). For example, if only 50%, rather than 70%, of the population was  
477 vaccinated for MERS-CoV, the median number of cases averted declined from 6 (95% PrI: 0-  
478 83) to 4 (95% PrI: 0-72). In contrast, if vaccination coverage was increased to 90%, then 7 (95%  
479 PrI: 0-93) MERS cases were averted. The number of MERS cases averted per 100,000 vaccine  
480 regimens administered decreased from 0.69 (95% PrI: 0-2.92) at 70% coverage, to 0.64 (95%  
481 PrI: 0-3.55) at 50% coverage, and 0.63 (95% PrI: 0-2.54) at 90% coverage. The sensitivity of  
482 the impact of outbreak response to other campaign parameters considered in our model,  
483 including per-exposure protection, time to protection following vaccination, vaccination coverage  
484 levels in HCWs, and one-dose vs. two-dose vaccines are provided in Figure 6. The sensitivity  
485 analyses for the other pathogens (NiV, LASV, and RVFV) and for different catchment levels are  
486 provided in the Supplement (SI Text). In general, the number of cases averted were highest  
487 when the spatial scale for vaccine response (catchment area) was the first administrative level,  
488 but the per-regimen vaccination impact was higher for the smaller catchment areas (second



489 administrative level or hospital-based catchment areas), because fewer vaccine regimens were  
 490 required per campaign in those areas (Figures S33-S34).  
 491  
 492



494 **Figure 6. Vaccine impact sensitivity analysis for MERS-CoV.** Sensitivity of vaccination  
495 impact for MERS-CoV to variation in different campaign parameters expressed as (A) fraction of  
496 cases averted, (B) cases averted per 100,000 vaccinated in the general population, and (C)  
497 cases averted per 1,000 health care workers (HCWs) vaccinated.

498

## 499 **Discussion**

500

### 501 *Model performance*

502

503 Our spillover simulation model estimates closely matched the average annual reported number  
504 of spillover cases for each pathogen, as well as the observed interannual variability in the  
505 number of spillover cases that have occurred in the past few decades. The simulation results  
506 also captured the geographic distribution and seasonality of spillover cases for each pathogen.  
507 The magnitude, spatial distribution, and timing of spillover rates are the main determinants of  
508 how frequently an outbreak response threshold will be triggered and therefore the size of the  
509 vaccine stockpile needed for outbreak response. Although these patterns could shift to some  
510 degree in the future, our model represents what we know about them presently. In addition to  
511 influencing stockpile size, these three factors are also relevant for logistical considerations such  
512 as the geographic location(s) of the stockpile and the necessary stockpile replenishment rate  
513 (Yen et al. 2015).

514

### 515 *Stockpile estimates*

516

517 The estimated number of vaccine regimens needed to reach vaccination coverage targets in the  
518 general population varied considerably across the four pathogens examined. For both LASV  
519 and NiV, the median was zero, indicating that reactive vaccination campaigns would not be  
520 triggered more than 50% of the time. In contrast, the median numbers of vaccine regimens  
521 needed for MERS-CoV and RVFV were 870,000 and 1,190,000, respectively. However, the  
522 95% prediction intervals for all four pathogens were wide due to spatial and temporal  
523 heterogeneity in spillover rates and overdispersion in outbreak sizes resulting from human-to-  
524 human transmission. For all four pathogens, the vaccine regimens needed to target HCWs were  
525 several orders of magnitude lower than needed to target the general population.

526

527 These results indicate that the size of the vaccine stockpile needed to meet annual reactive  
528 vaccination demands will depend on the pathogen's epidemiology, the vaccine coverage  
529 strategy, and the specific demands of a sustainable manufacturing strategy. In addition to the  
530 median or mean annual vaccine demand, our estimates also provide an estimate of the inter-  
531 annual variability in vaccine demand and the potential magnitude of vaccine demand in low-  
532 frequency, but high-demand years. For example, the 75th or 90th percentile of our estimates  
533 correspond to the level of demand experienced once every four or ten years, on average. The  
534 desired size of a vaccine stockpile will likely depend not only on the average annual vaccine  
535 demand, but also on the stockpile capacity needed to adequately handle the unpredictability in  
536 the timing, frequency, geography, and magnitude of outbreaks. These questions will depend on  
537 sustainable vaccine manufacturing capacity, the geographic distribution of both this

538 manufacturing capacity and the stockpile, and vaccine shelf life. A graphical user interface is  
539 available at <http://eidvaccinedemand.crc.nd.edu> to facilitate interactive exploration of these  
540 dependencies.

541  
542 Our vaccine demand estimates indicate that the biggest determinant of the size of the reactive  
543 vaccine stockpile needs was the vaccination strategy: targeting the general population, only  
544 HCWs, or ring vaccination. For pathogens that primarily cause nosocomial outbreaks (e.g.,  
545 LASV), vaccinating HCWs can protect high-risk individuals. In our analysis, this strategy had a  
546 larger impact in terms of cases averted per vaccine regimen than vaccinating the general  
547 population. The impact of vaccinating HCWs will be highest when spillovers are highly spatially  
548 clustered because vaccination campaigns are more likely to be triggered in high-spillover  
549 catchment areas, thereby protecting HCWs against nosocomial transmission in areas where  
550 vaccination has already occurred earlier in the transmission season but where the spillover risk  
551 may remain high. A ring vaccination strategy would also require significantly fewer regimens  
552 than a general vaccination strategy. We estimated that the vaccine demand under a ring  
553 vaccination strategy would be similar to the demand under a HCW-vaccination strategy for  
554 LASV, NiV, and MERS-CoV, and moderately higher than the HCW-vaccination strategy for  
555 RVFV. Another strategy to reduce the number of vaccine regimens needed per reactive  
556 campaign that we did not consider in our analysis would be to target high-risk sub-populations  
557 instead of the whole population of a catchment area. In the case of RVFV, this would be animal  
558 workers like butchers, veterinarians, and farmers who are at highest risk of infection (Wilson et  
559 al. 1994; Nyakarahuka et al. 2018; Msimang et al. 2019). For MERS-CoV, camel workers have  
560 a higher risk of infection than the general population (Dudas et al. 2018). For LASV, rural  
561 populations within a catchment area are assumed to have a higher risk than urban populations  
562 (but see Chika-Igwenyi et al. 2021, where >50% of patients in one outbreak were urban  
563 residents). For NiV, rural populations and people drinking raw date palm sap could be targeted  
564 for vaccination (Rahman et al. 2012; Islam et al. 2016).

565  
566 In addition to providing an estimate of vaccine stockpile size, our modeling approach also  
567 provides an estimate of where the stockpile will most frequently need to be deployed. An  
568 understanding of the geographical distribution of vaccine demand is critical for sustainable  
569 manufacturing and timely response to outbreaks (Grais et al. 2008; Azman and Lessler 2015;  
570 Wells et al. 2019). Knowledge of vaccine needs by geographic area is essential so that the  
571 stockpile(s) can be strategically positioned for rapid deployment following the triggering of an  
572 outbreak response. Vaccine demand in a given area will be a function of the probability of an  
573 outbreak response being triggered and the size of the target population. Because we used a  
574 sliding time window for the outbreak threshold, the probability of a reactive vaccination  
575 campaign being triggered will also depend on the seasonality of spillover. Spillover cases that  
576 are highly seasonal will be more likely to trigger a response than spillovers that occur  
577 sporadically throughout the year. Highly seasonal spillover rates also increase the importance of  
578 rapid deployment of reactive vaccination campaigns, because the shorter duration of the  
579 transmission season increases the likelihood that any delays would cause campaigns to occur  
580 only after seasonal spillover transmission has declined.

581

582 The size of the outbreak-response catchment areas (our baseline catchment area at the 2nd  
583 administrative level vs. 1st administrative units or individual hospitals within each 1st  
584 administrative unit) also had a large impact on the frequency and timing of outbreak response.  
585 First-level administrative catchment areas triggered more outbreak responses and also have  
586 larger population sizes, and would therefore require a larger vaccine stockpile. However, this  
587 result assumes that the outbreak threshold (number of cases needed to trigger a reactive  
588 vaccination campaign) is the same regardless of the size of the catchment area. Adjusting the  
589 threshold size based on the geographic extent or population size of the catchment areas would  
590 alter the stockpile requirements and could be one approach to aligning expected stockpile  
591 demands with manufacturing capacity. The expected number of regimens needed for adm1  
592 catchment areas might also be an overestimate if only certain regions in an adm1 are at risk.  
593 Therefore, another approach that could balance the advantage of expanded adm1 catchment  
594 surveillance areas against the larger stockpile requirements would be to monitor spillover cases  
595 at the adm1 level, but limit reactive vaccination to the adm2 regions within the adm1 catchment  
596 area where spillover cases were observed.

597

### 598 *Vaccination impact*

599

600 Our results indicate that reactive vaccination strategies for preventing the transmission of  
601 zoonotic pathogens with  $R_0 < 1$  tend to have limited impacts. For each of the four pathogens we  
602 considered, reactive vaccination of the general population averted fewer than 100 cases per  
603 year on average and required more than 10,000 vaccine regimens per case averted. The  
604 largest impact (as measured by total cases averted or fraction of cases averted) was achieved  
605 for RVFV, which was the only pathogen where  $>5\%$  of total cases were averted via reactive  
606 vaccination under our default assumptions. On a cases-averted per regimen basis, vaccinating  
607 HCWs was more effective than vaccinating the general population for each of the pathogens  
608 with at least some human-to-human transmission in nosocomial settings (LASV, MERS-CoV,  
609 and NiV), suggesting that targeting this group may be a viable strategy for reducing the spread  
610 of zoonotic pathogens that are capable of nosocomial transmission.

611

612 Under our baseline reactive vaccination scenario, vaccination averted a higher proportion of  
613 RVF cases than cases of the other three diseases, even though we assumed that there was no  
614 human-to-human RVFV transmission. The higher impact of reactive vaccination for RVFV was  
615 the result of two factors. First, our default threshold to trigger an RVFV vaccination campaign  
616 was three cases (compared to 10 cases within a 28-day window for LASV or MERS-CoV),  
617 which led to more RVFV campaigns being triggered than for the other diseases. Second, RVFV  
618 spillovers are highly clustered in space and time, so additional spillover cases were often  
619 concentrated in catchment areas where previous spillovers during the transmission season had  
620 already triggered a reactive vaccination campaign. Although the lower threshold led to more  
621 vaccine regimens being required for RVFV than for the other pathogens, the per regimen impact  
622 of reactive vaccination was still highest for RVFV. These results highlight the importance of  
623 understanding the underlying epidemiology of zoonotic pathogens when assessing the  
624 feasibility of a reactive vaccination strategy. The spatial and temporal heterogeneity in spillover  
625 patterns will be a primary factor determining the potential impact of reactive vaccination for

626 pathogens where cases primarily occur via zoonotic spillover rather than human-to-human  
627 transmission. With a sensitive case threshold for triggering a vaccination campaign, and a  
628 relatively quick response time (28 days), our results indicate that ~25% of RVF cases could be  
629 averted. However, if the response time is slower (120 days), fewer than 5% of RVF cases would  
630 be averted via reactive vaccination. This highlights the importance of rapid response and  
631 vaccine deployment to the success of reactive campaigns when spillover is seasonal.

632  
633 After RVFV, the impact of vaccination was modestly higher for the pathogen (MERS-CoV) with  
634 the highest  $R_0$  (baseline  $R_0=0.58$ ), indicating that rapid deployment of a reactive vaccination  
635 campaign can avert a fraction of cases for pathogens capable of at least some sustained  
636 human-to-human transmission. However, even for MERS-CoV, fewer than 10% of annual cases  
637 were averted by reactive vaccination, even under our most optimistic scenario with a minimal  
638 delay. This was partly because a significant fraction of cases were spillover cases in geographic  
639 areas where no vaccination campaign was triggered, and partially because reactive vaccination  
640 often did not occur rapidly enough to avert a significant proportion of cases resulting from  
641 secondary human-to-human transmission. The one scenario where reactive vaccination had a  
642 large impact on MERS-CoV transmission was with a higher  $R_0$  value of 0.99. In this case, 84.0%  
643 (95% PrI: 10.7-97.5%) of MERS cases could be averted under our baseline reactive vaccination  
644 scenario, compared to only 2.1% (95% PrI: 0-18.2%) of cases averted with the default  $R_0=0.58$ .  
645 This result highlights the increased potential impact of a reactive vaccination strategy as  $R_0$   
646 approaches or exceeds one and self-sustaining human-to-human transmission chains that lead  
647 to larger outbreaks become more likely.

648  
649 *Reactive vs. prophylactic vaccination*

650  
651 Delays between the triggering of the outbreak threshold and vaccine administration limit the  
652 impact of reactive vaccination. In most simulated outbreaks, the outbreak died out before the  
653 vaccination was administered due to the low  $R_0$ . In light of this, prophylactic immunization of  
654 HCWs or people at high risk could have a larger impact than reactive vaccination. However, a  
655 potentially important aspect that was not considered in our study was the impact that reactive  
656 vaccination campaigns in one year had for protection in subsequent year(s). Depending on the  
657 duration of vaccine-derived immunity, the number of cases averted in subsequent years could  
658 be substantial, particularly if the geographic clustering of spillovers is fairly consistent from year  
659 to year. For example, in the past few years, some catchment areas in Nigeria have experienced  
660 outbreaks of Lassa fever multiple years in a row (Siddle et al. 2018; Roberts 2018). As an  
661 extension of our work, the number of averted cases in the years following a reactive vaccination  
662 campaign could be estimated based on the spillover rate, the probability of an outbreak, and the  
663 durability of vaccine-derived immunity.

664  
665 *Limitations*

666  
667 We have attempted to estimate vaccine stockpile needs and identify the most important  
668 determinants of success for reactive vaccination of zoonotic emerging pathogens by modeling  
669 several vaccination strategies and exploring the sensitivity of our results to different aspects of

670 pathogen natural history and vaccine deployment. However, there are some limitations to our  
671 approach that could affect these estimates. We briefly mention the main limitations here and  
672 include an expanded discussion of these limitations in the SI Text.

673  
674 First, there is a relatively poor understanding of the epidemiology of most emerging zoonotic  
675 pathogens, and data that could be used to try and elucidate the most important aspects of their  
676 epidemiology is limited (Grange et al. 2021). In this study, we collated epidemiological data and  
677 parameter estimates from a variety of published sources and also consulted pathogen-specific  
678 experts, but, inevitably, our approach was limited by current knowledge. Second, because the  
679 modeling framework is intended to be applicable for a range of emerging zoonotic pathogens, it  
680 cannot incorporate all of the specific epidemiological details that might affect vaccine demand or  
681 impact for a particular pathogen. Our focus was on the key aspects of epidemiology and  
682 outbreak response that influence sustainable manufacturing needs, vaccine stockpile  
683 requirements, and the impact of outbreak response. Third, we only considered reported cases  
684 when estimating pathogen spillover rates, because undiagnosed or unreported infections would  
685 not trigger an outbreak response, which could bias the geographic distribution of vaccine  
686 demand away from areas with limited disease surveillance systems. This decision was made to  
687 ensure that our framework could be implemented with existing data only, and therefore could be  
688 applied to other pathogens in a straightforward manner.

689  
690 Fourth, because the extent of community transmission for each of the study pathogens is poorly  
691 understood, we assumed that human-to-human transmission was limited to nosocomial  
692 settings, which could result in an underestimate of vaccine demand. However, our modeling  
693 framework could be used to explicitly represent community transmission dynamics, and for  
694 pathogens with  $R_0 \ll 1$ , as was largely the case in this study, the limited size of the modeled  
695 transmission chains would be similar in either a community or hospital setting since we did not  
696 restrict the potential number of contacts per index case. Fifth, we also assumed that all  
697 nosocomial transmission was from patients to HCWs or between HCWs, and that there was no  
698 patient-to-patient or HCW-to-patient transmission. Therefore, our estimates of the impact of  
699 vaccinating HCWs represents an upper-bound on the effectiveness of this strategy, as  
700 instances of patient-to-patient transmission would not be prevented via this strategy. Sixth,  
701 another simplifying assumption of our model is that cases in one catchment area do not lead to  
702 transmission or an outbreak outside of that catchment area. However, our model already  
703 implicitly incorporates the possibility of spread between catchment areas, and although our  
704 model does not predict spillover cases occurring outside of each pathogen's currently  
705 documented geographic distribution, the reactive vaccination strategies we examined should  
706 also be applicable for responding to imported cases and their associated outbreaks. Finally, we  
707 did not consider any targeted vaccination strategies beyond ring vaccination or targeting  
708 healthcare workers to limit nosocomial outbreaks.

709  
710 *Conclusion*

711  
712 To inform the development of sustainable vaccine manufacturing processes for emerging  
713 pathogens, we developed a modeling framework to estimate the necessary reactive vaccine

714 stockpile size for emerging zoonotic pathogens. Our framework provides a flexible methodology  
715 for estimating vaccine stockpile needs for outbreak response, and for exploring the impact of  
716 epidemiology and vaccination strategies on outcomes that have important logistical implications  
717 for sustainable vaccine manufacturing, such as the geographic distribution of demand or the  
718 required stockpile replenishment rate. However, our model showed that the impact of reactive  
719 vaccination for the four pathogens that we explored was minimal, preventing fewer than 10% of  
720 human cases under most scenarios with their current epidemiology. However, all these  
721 pathogens are closely monitored for their outbreak potential, and control measures are needed.  
722 Targeting populations at higher risk of infection, such as HCWs, had a higher per-regimen  
723 impact than population-wide vaccination in outbreak control situations. Our results highlight the  
724 need for a more thorough epidemiological understanding of these, and other, emerging zoonotic  
725 pathogens. Improved pathogen surveillance and case detection are also essential for improving  
726 the model and our estimates of vaccine demand. Further work exploring additional scenarios,  
727 such as the possibility of targeting certain high-risk populations or the potential uses of vaccines  
728 for outbreak prevention rather than just outbreak response, is also needed to improve the  
729 potential impacts of vaccination.

730

### 731 **Acknowledgements**

732

733 We thank Jim Robinson of CEPI and several members of the CEPI Scientific Advisory  
734 committee for helping formulate the reactive vaccination strategies examined in this manuscript  
735 and for providing feedback on our modeling framework. We thank John Edmunds (LASV),  
736 Robert Sumaye (RVFV), Bart Haagmans (MERS-CoV), Emily Gurley (NiV), and Steve Luby  
737 (NiV) for serving as pathogen-specific experts and providing assistance with identifying key  
738 epidemiological features and data gaps for their respective pathogens. We thank Nico Vandaele  
739 for feedback on how epidemiological modeling can help inform the planning and development of  
740 sustainable vaccine manufacturing. We thank Shweta Bansal and Romain Garnier for  
741 discussions regarding the modeling of emerging infectious disease outbreaks and vaccination.

742

### 743 **Funding**

744

745 The following authors were supported by a contract from CEPI to the University of Notre Dame:  
746 AL, QAtB, QMT, JHH, ASS, ME, CH, KK, KS, MW, TAP, SMM.

747 **Supplementary Information**

748

749 **Table S1. Overview of data references.**

750 **Figure S1. Spillover and reactive vaccination patterns for Lassa fever virus (LASV).**

751 **Figure S2. Spillover and reactive vaccination patterns for Middle Eastern respiratory**

752 **virus (MERS-CoV).**

753 **Figure S3. Spillover and reactive vaccination patterns for Nipah virus (NiV).**

754 **Figure S4. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV).**

755 **SI Text. Sensitivity analysis.**

756 **Figures S5-S34 in SI Text.**

757

758

759



760 **References**

- 761
- 762
- 763 Ahmad, Khabir. 2000. "More Deaths from Rift Valley Fever in Saudi Arabia and Yemen." *The*  
764 *Lancet* 356 (9239): 1422.
- 765 Ajayi, Nnennaya A. 2013. "Containing a Lassa Fever Epidemic in a Resource-Limited Setting:  
766 Outbreak Description and Lessons Learned from Abakaliki, Nigeria (January–March  
767 2012)." *International Journal of Infectious Diseases: IJID: Official Publication of the*  
768 *International Society for Infectious Diseases* 17 (11): e1011–16.
- 769 Al-Hamdan, Nasser A., Anil A. Panackal, Tami H. Al Bassam, Abdullah Alrabea, Mohammed Al  
770 Hazmi, Yagoub Al Mazroa, Mohammed Al Jefri, Ali S. Khan, and Thomas G. Ksiazek.  
771 2015. "The Risk of Nosocomial Transmission of Rift Valley Fever." *PLoS Neglected*  
772 *Tropical Diseases* 9 (12): e0004314.
- 773 Ali, Mohammad, Amanda K. Debes, Francisco J. Luquero, Deok Ryun Kim, Je Yeon Park,  
774 Laura Digilio, Byomkesh Manna, et al. 2016. "Potential for Controlling Cholera Using a  
775 Ring Vaccination Strategy: Re-Analysis of Data from a Cluster-Randomized Clinical  
776 Trial." *PLoS Medicine* 13 (9): e1002120.
- 777 Andersen, Kristian G., Andrew Rambaut, W. Ian Lipkin, Edward C. Holmes, and Robert F.  
778 Garry. 2020. "The Proximal Origin of SARS-CoV-2." *Nature Medicine* 26 (4): 450–52.
- 779 Anthony, S. J., K. Gilardi, V. D. Menachery, T. Goldstein, B. Ssebide, R. Mbabazi, I. Navarrete-  
780 Macias, et al. 2017. "Further Evidence for Bats as the Evolutionary Source of Middle  
781 East Respiratory Syndrome Coronavirus." *MBio* 8 (2).  
782 <https://doi.org/10.1128/mBio.00373-17>.
- 783 Antia, Rustom, Roland R. Regoes, Jacob C. Koella, and Carl T. Bergstrom. 2003. "The Role of  
784 Evolution in the Emergence of Infectious Diseases." *Nature* 426 (6967): 658–61.
- 785 Anyamba, Assaf, Jean-Paul Chretien, Jennifer Small, Compton J. Tucker, Pierre B. Formenty,  
786 Jason H. Richardson, Seth C. Britch, David C. Schnabel, Ralph L. Erickson, and  
787 Kenneth J. Linthicum. 2009. "Prediction of a Rift Valley Fever Outbreak." *Proceedings of*  
788 *the National Academy of Sciences of the United States of America* 106 (3): 955–59.
- 789 Anyamba, Assaf, Kenneth J. Linthicum, Jennifer Small, Seth C. Britch, Edwin Pak, Stephane de  
790 La Rocque, Pierre Formenty, et al. 2010. "Prediction, Assessment of the Rift Valley  
791 Fever Activity in East and Southern Africa 2006–2008 and Possible Vector Control  
792 Strategies." *The American Journal of Tropical Medicine and Hygiene* 83 (2\_Suppl): 43–  
793 51.
- 794 Archer, B. N., J. Thomas, J. Weyer, A. Cengimbo, D. E. Landoh, C. Jacobs, S. Ntuli, et al. 2013.  
795 "Epidemiologic Investigations into Outbreaks of Rift Valley Fever in Humans, South  
796 Africa, 2008-2011." *Emerging Infectious Diseases* 19 (12).  
797 <https://doi.org/10.3201/eid1912.121527>.
- 798 Arunkumar, Govindakarnavar, Radhakrishnan Chandni, Devendra T. Mourya, Sujeet K. Singh,  
799 Rajeev Sadanandan, Preeti Sudan, Balram Bhargava, and Nipah Investigators People  
800 and Health Study Group. 2019. "Outbreak Investigation of Nipah Virus Disease in  
801 Kerala, India, 2018." *The Journal of Infectious Diseases* 219 (12): 1867–78.
- 802 Assiri, Abdullah, Jaffar A. Al-Tawfiq, Abdullah A. Al-Rabeeah, Fahad A. Al-Rabiah, Sami Al-  
803 Hajjar, Ali Al-Barrak, Hesham Flemban, et al. 2013. "Epidemiological, Demographic, and  
804 Clinical Characteristics of 47 Cases of Middle East Respiratory Syndrome Coronavirus  
805 Disease from Saudi Arabia: A Descriptive Study." *The Lancet Infectious Diseases* 13 (9):  
806 752–61.
- 807 Assiri, Abdullah, Allison McGeer, Trish M. Perl, Connie S. Price, Abdullah A. Al Rabeeah, Derek  
808 A. T. Cummings, Zaki N. Alabdullatif, et al. 2013. "Hospital Outbreak of Middle East  
809 Respiratory Syndrome Coronavirus." *The New England Journal of Medicine* 369 (5):

- 810 407–16.
- 811 Bernasconi, Valentina, Paul A. Kristiansen, Mike Whelan, Raúl Gómez Román, Alison Bettis,  
812 Solomon Abebe Yimer, Céline Gurry, et al. 2020. “Developing Vaccines against  
813 Epidemic-Prone Emerging Infectious Diseases.” *Bundesgesundheitsblatt,*  
814 *Gesundheitsforschung, Gesundheitsschutz* 63 (1): 65–73.
- 815 Bird, Brian H., Thomas G. Ksiazek, Stuart T. Nichol, and N. James Maclachlan. 2009. “Rift  
816 Valley Fever Virus.” *Journal of the American Veterinary Medical Association* 234 (7):  
817 883–93.
- 818 Bob, Ndeye Sakha, Hampâté Bâ, Gamou Fall, Elkhailil Ishagh, Mamadou Y. Diallo,  
819 Abdourahmane Sow, Pape Mbacké Sembene, et al. 2017. “Detection of the  
820 Northeastern African Rift Valley Fever Virus Lineage During the 2015 Outbreak in  
821 Mauritania.” *Open Forum Infectious Diseases* 4 (2). <https://doi.org/10.1093/ofid/ofx087>.
- 822 Bowen, G. S., O. Tomori, H. Wulff, J. Casals, A. Noonan, and W. G. Downs. 1975. “Lassa Fever  
823 in Onitsha, East Central State, Nigeria in 1974.” *Bulletin of the World Health*  
824 *Organization* 52 (4–6): 599–604.
- 825 Breban, Romulus, Julien Riou, and Arnaud Fontanet. 2013. “Interhuman Transmissibility of  
826 Middle East Respiratory Syndrome Coronavirus: Estimation of Pandemic Risk.” *The*  
827 *Lancet* 382 (9893): 694–99.
- 828 Bron, Gebbiena M., Kathryn Strimbu, Helene Cecilia, Anita Lerch, Sean M. Moore, Quan Tran,  
829 T. Alex Perkins, and A. Quirine. 2021. “Over 100 Years of Rift Valley Fever: A Patchwork  
830 of Data on Pathogen Spread and Spillover.” *MedRxiv*.  
831 <https://www.medrxiv.org/content/10.1101/2021.02.18.21251916v1.abstract>.
- 832 Brooks, Mollie E., Kasper Kristensen, Koen J. Van Benthem, Arni Magnusson, Casper W. Berg,  
833 Anders Nielsen, Hans J. Skaug, Martin Machler, and Benjamin M. Bolker. 2017.  
834 “GlmTMB Balances Speed and Flexibility among Packages for Zero-Inflated  
835 Generalized Linear Mixed Modeling.” *The R Journal* 9 (2): 378–400.
- 836 Bubar, Kate M., Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah Cobey, Yonatan H.  
837 Grad, and Daniel B. Larremore. 2021. “Model-Informed COVID-19 Vaccine Prioritization  
838 Strategies by Age and Serostatus.” *Science*. <https://doi.org/10.1126/science.abe6959>.
- 839 Carey, D. E., G. E. Kemp, H. A. White, L. Pinneo, R. F. Addy, A. L. Fom, G. Stroh, J. Casals,  
840 and B. E. Henderson. 1972. “Lassa Fever. Epidemiological Aspects of the 1970  
841 Epidemic, Jos, Nigeria.” *Transactions of the Royal Society of Tropical Medicine and*  
842 *Hygiene* 66 (3): 402–8.
- 843 Cauchemez, Simon, Christophe Fraser, Maria D. Van Kerkhove, Christl A. Donnelly, Steven  
844 Riley, Andrew Rambaut, Vincent Enouf, Sylvie van der Werf, and Neil M. Ferguson.  
845 2014. “Middle East Respiratory Syndrome Coronavirus: Quantification of the Extent of  
846 the Epidemic, Surveillance Biases, and Transmissibility.” *The Lancet Infectious Diseases*  
847 14 (1): 50–56.
- 848 Cauchemez, Simon, Pierre Nouvellet, Anne Cori, Thibaut Jombart, Tini Garske, Hannah  
849 Clapham, Sean Moore, et al. 2016. “Unraveling the Drivers of MERS-CoV  
850 Transmission.” *Proceedings of the National Academy of Sciences of the United States of*  
851 *America* 113 (32): 9081–86.
- 852 Centers for Disease Control and Prevention (CDC). 1998. “Rift Valley Fever -- East Africa,  
853 1997-1998.” *MMWR Morb Mortal Wkly Rep* 47 (13): 261–64.
- 854 ———. 2007. “Rift Valley Fever Outbreak --- Kenya, November 2006--January 2007.” *MMWR*  
855 *Morb Mortal Wkly Rep* 56 (4): 73–76.
- 856 ———. 2020. “Outbreak Summaries: Rift Valley Fever.” June 1, 2020.  
857 <https://www.cdc.gov/vhf/rvf/outbreaks/summaries.html>.
- 858 CEPI. 2018. “Priority Diseases – CEPI.” December 12, 2018.  
859 [https://cepi.net/research\\_dev/priority-diseases/](https://cepi.net/research_dev/priority-diseases/).
- 860 Chan, K. P., P. E. Rollin, T. G. Ksiazek, Y. S. Leo, K. T. Goh, N. I. Paton, E. H. Sng, and A. E.

- 861 Ling. 2002a. "A Survey of Nipah Virus Infection among Various Risk Groups in  
862 Singapore." *Epidemiology and Infection* 128 (1): 93–98.
- 863 ———. 2002b. "A Survey of Nipah Virus Infection among Various Risk Groups in Singapore."  
864 *Epidemiology & Infection* 128 (1): 93–98.
- 865 Chowell, Gerardo, Seth Blumberg, Lone Simonsen, Mark A. Miller, and Cécile Viboud. 2014.  
866 "Synthesizing Data and Models for the Spread of MERS-CoV, 2013: Key Role of Index  
867 Cases and Hospital Transmission." *Epidemics* 9 (December): 40–51.
- 868 CSR. n.d. "World Health Organization - Eastern Mediterranean Region." Accessed March 19,  
869 2019. [http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-  
870 update-february-2019.html](http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-february-2019.html).
- 871 Daubney, R., J. R. Hudson, and P. C. Garnham. 1931. "Enzootic Hepatitis or Rift Valley Fever.  
872 An Undescribed Virus Disease of Sheep Cattle and Man from East Africa." *The Journal  
873 of Pathology and Bacteriology* 34 (4): 545–79.
- 874 Dudas, Gytis, Luiz Max Carvalho, Andrew Rambaut, and Trevor Bedford. 2018. "MERS-CoV  
875 Spillover at the Camel-Human Interface." *ELife* 7 (January).  
876 <https://doi.org/10.7554/eLife.31257>.
- 877 E Keane, H. M. Gilles. 1977. "Lassa Fever in Panguma Hospital, Sierra Leone, 1973-6." *British  
878 Medical Journal* 1 (6073): 1399.
- 879 Excler, Jean-Louis, Melanie Saville, Seth Berkley, and Jerome H. Kim. 2021. "Vaccine  
880 Development for Emerging Infectious Diseases." *Nature Medicine* 27 (4): 591–600.
- 881 FAO. 2017. "Rift Valley Fever in Niger: Risk Assessment."  
882 <http://www.fao.org/3/i7055e/i7055e.pdf>.
- 883 Farrington, C. P., M. N. Kanaan, and N. J. Gay. 2003. "Branching Process Models for  
884 Surveillance of Infectious Diseases Controlled by Mass Vaccination." *Biostatistics* 4 (2):  
885 279–95.
- 886 Faye, Ousmane, Mawlouth Diallo, Djibril Diop, O. Elmamy Bezeid, Hampathé Bâ, Mbayame  
887 Niang, Ibrahima Dia, et al. 2007. "Rift Valley Fever Outbreak with East-Central African  
888 Virus Lineage in Mauritania, 2003." *Emerging Infectious Diseases* 13 (7): 1016.
- 889 Findlay, G. M. 1932. "Rift Valley Fever or Enzootic Hepatitis." *Transactions of the Royal Society  
890 of Tropical Medicine and Hygiene* 25 (4): 229-IN11.
- 891 Fisher-Hoch, S. P., O. Tomori, A. Nasidi, G. I. Perez-Oronoz, Y. Fakile, L. Hutwagner, and J. B.  
892 McCormick. 1995. "Review of Cases of Nosocomial Lassa Fever in Nigeria: The High  
893 Price of Poor Medical Practice." *BMJ* 311 (7009): 857–59.
- 894 Frame, J. D., J. M. Baldwin Jr, D. J. Gocke, and J. M. Troup. 1970. "Lassa Fever, a New Virus  
895 Disease of Man from West Africa. I. Clinical Description and Pathological Findings." *The  
896 American Journal of Tropical Medicine and Hygiene* 19 (4): 670–76.
- 897 Francis, T., and T. P. Magill. 1935. "RIFT VALLEY FEVER : A REPORT OF THREE CASES OF  
898 LABORATORY INFECTION AND THE EXPERIMENTAL TRANSMISSION OF THE  
899 DISEASE TO FERRETS." *The Journal of Experimental Medicine* 62 (3): 433–48.
- 900 Fraser, D. W., C. C. Campbell, T. P. Monath, P. A. Goff, and M. B. Gregg. 1974. "Lassa Fever  
901 in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic Studies." *The  
902 American Journal of Tropical Medicine and Hygiene* 23 (6): 1131–39.
- 903 Gerken, Keli N., A. Desiree LaBeaud, Henshaw Mandi, Maina L'Azou Jackson, J. Gabrielle  
904 Breugelmans, and Charles H. King. 2021. "Paving the Way for Human Vaccination  
905 against Rift Valley Fever Virus: 1 A Systematic Literature Review of RVFV Epidemiology  
906 from 1999 to 2021." *MedRxiv*. <https://doi.org/10.1101/2021.09.29.21264307>.
- 907 Gibb, Rory, Lina M. Moses, David W. Redding, and Kate E. Jones. 2017. "Understanding the  
908 Cryptic Nature of Lassa Fever in West Africa." *Pathogens and Global Health* 111 (6):  
909 276–88.
- 910 Girish Kumar, C. P., Attayur P. Sugunan, Pragma Yadav, Karishma Krishna Kurup, Renjith  
911 Aarathie, Ponnaiah Manickam, Tarun Bhatnagar, et al. 2019. "Infections among

- 912           Contacts of Patients with Nipah Virus, India.” *Emerging Infectious Diseases Journal* 25  
913           (5). <https://doi.org/10.3201/eid2505.181352>.
- 914   Gouglas, Dimitrios, Mario Christodoulou, Stanley A. Plotkin, and Richard Hatchett. 2019. “CEPI:  
915           Driving Progress Toward Epidemic Preparedness and Response.” *Epidemiologic*  
916           *Reviews* 41 (1): 28–33.
- 917   Grange, Zoë L., Tracey Goldstein, Christine K. Johnson, Simon Anthony, Kirsten Gilardi, Peter  
918           Daszak, Kevin J. Olival, et al. 2021. “Ranking the Risk of Animal-to-Human Spillover for  
919           Newly Discovered Viruses.” *Proceedings of the National Academy of Sciences of the*  
920           *United States of America* 118 (15). <https://doi.org/10.1073/pnas.2002324118>.
- 921   Group, The Who Mers-Cov Research, and The WHO MERS-CoV Research Group. 2013.  
922           “State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus  
923           (MERS-CoV) in Humans.” *PLoS Currents*.  
924           <https://doi.org/10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8>.
- 925   Gurley, Emily S., Joel M. Montgomery, M. Jahangir Hossain, Michael Bell, Abul Kalam Azad,  
926           Mohammed Rafiqul Islam, Mohammed Abdur Rahim Molla, et al. 2007. “Person-to-  
927           Person Transmission of Nipah Virus in a Bangladeshi Community.” *Emerging Infectious*  
928           *Diseases* 13 (7): 1031–37.
- 929   Gurley, Emily S., Joel M. Montgomery, M. Jahangir Hossain, M. Rafiqul Islam, M. Abdur Rahim  
930           Molla, S. M. Shamsuzzaman, Kazi Akram, et al. 2007. “Risk of Nosocomial  
931           Transmission of Nipah Virus in a Bangladesh Hospital.” *Infection Control and Hospital*  
932           *Epidemiology: The Official Journal of the Society of Hospital Epidemiologists of America*  
933           28 (6): 740–42.
- 934   Hamblion, E. L., P. Raftery, A. Wendland, E. Dweh, G. S. Williams, R. N. C. George, L. Soro, et  
935           al. 2018. “The Challenges of Detecting and Responding to a Lassa Fever Outbreak in an  
936           Ebola-Affected Setting.” *International Journal of Infectious Diseases: IJID: Official*  
937           *Publication of the International Society for Infectious Diseases* 66 (January): 65–73.
- 938   Henao-Restrepo, Ana Maria, Anton Camacho, Ira M. Longini, Conall H. Watson, W. John  
939           Edmunds, Matthias Egger, Miles W. Carroll, et al. 2017. “Efficacy and Effectiveness of  
940           an RVS-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the  
941           Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!).” *The*  
942           *Lancet*. [https://doi.org/10.1016/s0140-6736\(16\)32621-6](https://doi.org/10.1016/s0140-6736(16)32621-6).
- 943   Hoogstraal, H., J. M. Meegan, G. M. Khalil, and F. K. Adham. 1979. “The Rift Valley Fever  
944           Epizootic in Egypt 1977-78. 2. Ecological and Entomological Studies.” *Transactions of*  
945           *the Royal Society of Tropical Medicine and Hygiene* 73 (6): 624–29.
- 946   Hsu, Vincent P., Mohammed Jahangir Hossain, Umesh D. Parashar, Mohammed Monsur Ali,  
947           Thomas G. Ksiazek, Ivan Kuzmin, Michael Niezgod, Charles Rupprecht, Joseph  
948           Bresee, and Robert F. Breiman. 2004. “Nipah Virus Encephalitis Reemergence,  
949           Bangladesh.” *Emerging Infectious Diseases* 10 (12): 2082–87.
- 950   Hui, David S., Esam I. Azhar, Yae-Jean Kim, Ziad A. Memish, Myoung-Don Oh, and Alimuddin  
951           Zumla. 2018. “Middle East Respiratory Syndrome Coronavirus: Risk Factors and  
952           Determinants of Primary, Household, and Nosocomial Transmission.” *The Lancet*  
953           *Infectious Diseases* 18 (8): e217–27.
- 954   Huneycutt, Brenda, Nicole Lurie, Sara Rotenberg, Richard Wilder, and Richard Hatchett. 2020.  
955           “Finding Equipose: CEPI Revises Its Equitable Access Policy.” *Vaccine* 38 (9): 2144–  
956           48.
- 957   Islam, M. Saiful, Hossain M. S. Sazzad, Syed Moinuddin Satter, Sharmin Sultana, M. Jahangir  
958           Hossain, Murshid Hasan, Mahmudur Rahman, et al. 2016. “Nipah Virus Transmission  
959           from Bats to Humans Associated with Drinking Traditional Liquor Made from Date Palm  
960           Sap, Bangladesh, 2011-2014.” *Emerging Infectious Diseases* 22 (4): 664–70.
- 961   Jouan, A., B. Le Guenno, J. P. Digoutte, B. Philippe, O. Riou, and F. Adam. 1988. “An RVF  
962           Epidemic in Southern Mauritania.” *Annales de l'Institut Pasteur. Virology* 139 (3).

- 963 [https://doi.org/10.1016/s0769-2617\(88\)80046-7](https://doi.org/10.1016/s0769-2617(88)80046-7).
- 964 Kernéis, Solen, Lamine Koivogui, N'faly Magassouba, Kekoura Koulemou, Rosamund Lewis,  
965 Aristide Aplogan, Rebecca F. Grais, Philippe J. Guerin, and Elisabeth Fichet-Calvet.  
966 2009. "Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest  
967 Region of Guinea: A Cross-Sectional Study." *PLoS Neglected Tropical Diseases*.  
968 <https://doi.org/10.1371/journal.pntd.0000548>.
- 969 Khan, S. H., A. Goba, M. Chu, C. Roth, T. Healing, A. Marx, J. Fair, et al. 2008. "New  
970 Opportunities for Field Research on the Pathogenesis and Treatment of Lassa Fever."  
971 *Antiviral Research* 78 (1): 103–15.
- 972 Ki, Moran. 2015. "2015 MERS Outbreak in Korea: Hospital-to-Hospital Transmission."  
973 *Epidemiology and Health* 37 (July): e2015033.
- 974 Kitchen, S. F. 1934. "Laboratory Infections with the Virus of Rift Valley Fever 1." *The American  
975 Journal of Tropical Medicine and Hygiene* s1-14 (6): 547–64.
- 976 Kucharski, A. J., and C. L. Althaus. 2015. "The Role of Superspreading in Middle East  
977 Respiratory Syndrome Coronavirus (MERS-CoV) Transmission." *Euro Surveillance:  
978 Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease  
979 Bulletin* 20 (25): 14–18.
- 980 Kumar, C. P. Girish, Attayur P. Sugunan, Pragya Yadav, Karishma Krishna Kurup, Renjith  
981 Aarathie, Ponnaiah Manickam, Tarun Bhatnagar, et al. 2019. "Infections among  
982 Contacts of Patients with Nipah Virus, India." *Emerging Infectious Diseases* 25 (5):  
983 1007–10.
- 984 Laughlin, Larry W., James M. Meegan, Larry J. Strausbaugh, David M. Morens, and Raymond  
985 H. Watten. 1979. "Epidemic Rift Valley Fever in Egypt: Observations of the Spectrum of  
986 Human Illness." *Transactions of the Royal Society of Tropical Medicine and Hygiene* 73  
987 (6): 630–33.
- 988 Lee, Elizabeth C., Nikolas I. Wada, M. Kate Grabowski, Emily S. Gurley, and Justin Lessler.  
989 2020. "The Engines of SARS-CoV-2 Spread." *Science* 370 (6515): 406–7.
- 990 Linthicum, Kenneth J., Seth C. Britch, and Assaf Anyamba. 2016. "Rift Valley Fever: An  
991 Emerging Mosquito-Borne Disease." *Annual Review of Entomology* 61: 395–415.
- 992 Lo Iacono, G., A. A. Cunningham, E. Fichet-Calvet, R. F. Garry, D. S. Grant, S. H. Khan, M.  
993 Leach, et al. 2015. "Using Modelling to Disentangle the Relative Contributions of  
994 Zoonotic and Anthroponotic Transmission: The Case of Lassa Fever." *PLoS Neglected  
995 Tropical Diseases* 9 (1). <https://doi.org/10.1371/journal.pntd.0003398>.
- 996 Luby, Stephen P., M. Jahangir Hossain, Emily S. Gurley, Be Nazir Ahmed, Shakila Banu, Salah  
997 Uddin Khan, Nusrat Homaira, et al. 2009. "Recurrent Zoonotic Transmission of Nipah  
998 Virus into Humans, Bangladesh, 2001-2007." *Emerging Infectious Diseases* 15 (8):  
999 1229–35.
- 1000 Maina, Joseph, Paul O. Ouma, Peter M. Macharia, Victor A. Alegana, Benard Mitto, Ibrahimia  
1001 Socé Fall, Abdisalan M. Noor, Robert W. Snow, and Emelda A. Okiro. 2019. "A Spatial  
1002 Database of Health Facilities Managed by the Public Health Sector in Sub Saharan  
1003 Africa." *Scientific Data* 6 (1): 134.
- 1004 McCormick, J. B., P. A. Webb, J. W. Krebs, K. M. Johnson, and E. S. Smith. 1987. "A  
1005 Prospective Study of the Epidemiology and Ecology of Lassa Fever." *The Journal of  
1006 Infectious Diseases* 155 (3): 437–44.
- 1007 Medlock, Jan, and Alison P. Galvani. 2009. "Optimizing Influenza Vaccine Distribution." *Science*  
1008 325 (5948): 1705–8.
- 1009 "MERS-CoV Cases." n.d. Accessed December 4, 2020. [http://rambaut.github.io/MERS-  
1010 Tools/cases2.html](http://rambaut.github.io/MERS-Tools/cases2.html).
- 1011 Métras, Raphaëlle, Lisa Cavalerie, Laure Dommergues, Philippe Mérot, W. John Edmunds,  
1012 Matt J. Keeling, Catherine Cêtre-Sossah, and Eric Cardinale. 2016. "The Epidemiology  
1013 of Rift Valley Fever in Mayotte: Insights and Perspectives from 11 Years of Data." *PLoS*

- 1014 *Neglected Tropical Diseases* 10 (6). <https://doi.org/10.1371/journal.pntd.0004783>.
- 1015 Meulen, J. ter, O. Lenz, L. Koivogui, N. Magassouba, S. K. Kaushik, R. Lewis, and W. Aldis.
- 1016 2001. "Short Communication: Lassa Fever in Sierra Leone: UN Peacekeepers Are at
- 1017 Risk." *Tropical Medicine & International Health: TM & IH* 6 (1): 83–84.
- 1018 "Ministry of Health - Kingdom of Saudi Arabia." 2020. 2020.
- 1019 <https://www.moh.gov.sa/en/CCC/events/national/Pages/2020.aspx>.
- 1020 Monath, T. P. 1974. "Lassa Fever and Marburg Virus Disease." *WHO Chronicle* 28 (5).
- 1021 <https://pubmed.ncbi.nlm.nih.gov/4208764/>.
- 1022 Monath, T. P., P. E. Mertens, R. Patton, C. R. Moser, J. J. Baum, L. Pinneo, G. W. Gary, and R.
- 1023 E. Kissling. 1973. "A Hospital Epidemic of Lassa Fever in Zorzor, Liberia, March–April
- 1024 1972." *The American Journal of Tropical Medicine and Hygiene* 22 (6): 773–79.
- 1025 Morse, Stephen S., Jonna A. K. Mazet, Mark Woolhouse, Colin R. Parrish, Dennis Carroll,
- 1026 William B. Karesh, Carlos Zambrana-Torrel, W. Ian Lipkin, and Peter Daszak. 2012.
- 1027 "Prediction and Prevention of the next Pandemic Zoonosis." *The Lancet* 380 (9857):
- 1028 1956–65.
- 1029 Msimang, Veerle, Peter N. Thompson, Petrus Jansen van Vuren, Stefano Tempia, Claudia
- 1030 Cordel, Joe Kgaladi, Jimmy Khosa, et al. 2019. "Rift Valley Fever Virus Exposure
- 1031 amongst Farmers, Farm Workers, and Veterinary Professionals in Central South Africa."
- 1032 *Viruses* 11 (2). <https://doi.org/10.3390/v11020140>.
- 1033 Müller, Marcel A., Benjamin Meyer, Victor M. Corman, Malak Al-Masri, Abdulhafeez Turkestani,
- 1034 Daniel Ritz, Andrea Sieberg, et al. 2015. "Presence of Middle East Respiratory
- 1035 Syndrome Coronavirus Antibodies in Saudi Arabia: A Nationwide, Cross-Sectional,
- 1036 Serological Study." *The Lancet Infectious Diseases*. [https://doi.org/10.1016/s1473-](https://doi.org/10.1016/s1473-3099(15)70090-3)
- 1037 [3099\(15\)70090-3](https://doi.org/10.1016/s1473-3099(15)70090-3).
- 1038 Mundel, B., and J. Gear. 1951. "Rift Valley Fever; I. The Occurrence of Human Cases in
- 1039 Johannesburg." *South African Medical Journal = Suid-Afrikaanse Tydskrif Vir*
- 1040 *Geneeskunde* 25 (44): 797–800.
- 1041 Munyua, Peninah M., Isaac Ngere, Elizabeth Hunsperger, Adano Kochi, Patrick Amoth, Lydia
- 1042 Mwasi, Suxiang Tong, et al. 2021. "Low-Level Middle East Respiratory Syndrome
- 1043 Coronavirus among Camel Handlers, Kenya, 2019." *Emerging Infectious Diseases* 27
- 1044 (4): 1201–5.
- 1045 Mylne, Adrian Q. N., David M. Pigott, Joshua Longbottom, Freya Shearer, Kirsten A. Duda,
- 1046 Jane P. Messina, Daniel J. Weiss, Catherine L. Moyes, Nick Golding, and Simon I. Hay.
- 1047 2015. "Mapping the Zoonotic Niche of Lassa Fever in Africa." *Transactions of the Royal*
- 1048 *Society of Tropical Medicine and Hygiene* 109 (8): 483–92.
- 1049 Nderitu, Leonard, John S. Lee, Jared Omolo, Sylvia Omulo, Monica L. O'Guinn, Allen
- 1050 Hightower, Fausta Mosha, et al. 2010. "Sequential Rift Valley Fever Outbreaks in
- 1051 Eastern Africa Caused by Multiple Lineages of the Virus." *The Journal of Infectious*
- 1052 *Diseases* 203 (5): 655–65.
- 1053 "Nigeria Centre for Disease Control." n.d. Accessed December 31, 2020.
- 1054 <https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria>.
- 1055
- 1056 Nikolay, Birgit. 2019. "Transmission of Nipah Virus - 14 Years of Investigations in Bangladesh."
- 1057 *The New England Journal of Medicine* 380 (19): 1804–14.
- 1058 Nikolay, Birgit, Henrik Salje, M. Jahangir Hossain, A. K. M. Dawlat Khan, Hossain M. S. Sazzad,
- 1059 Mahmudur Rahman, Peter Daszak, Ute Ströher, Juliet R. C. Pulliam, A. Marm Kilpatrick,
- 1060 Stuart T. Nichol, et al. 2019. "Transmission of Nipah Virus - 14 Years of Investigations in
- 1061 Bangladesh." *The New England Journal of Medicine* 380 (19): 1804–14.
- 1062 Nikolay, Birgit, Henrik Salje, M. Jahangir Hossain, Akm Dawlat Khan, Hossain M. S. Sazzad,
- 1063 Mahmudur Rahman, Peter Daszak, Ute Ströher, Juliet R. C. Pulliam, A. Marm Kilpatrick,
- 1064 and Others. 2019. "Transmission of Nipah Virus—14 Years of Investigations in

- 1065 Bangladesh." *The New England Journal of Medicine* 380 (19): 1804–14.
- 1066 Nyakarahuka, Luke, Annabelle de St Maurice, Lawrence Purpura, Elizabeth Ervin, Stephen
- 1067 Balinandi, Alex Tumusiime, Jackson Kyondo, et al. 2018. "Prevalence and Risk Factors
- 1068 of Rift Valley Fever in Humans and Animals from Kabale District in Southwestern
- 1069 Uganda, 2016." *PLoS Neglected Tropical Diseases* 12 (5): e0006412.
- 1070 O'Hearn, Aileen E., Matthew A. Voorhees, David P. Fetterer, Nadia Wauquier, Moinya R.
- 1071 Coomber, James Bangura, Joseph N. Fair, Jean-Paul Gonzalez, and Randal J.
- 1072 Schoepp. 2016. "Serosurveillance of Viral Pathogens Circulating in West Africa." *Virology Journal* 13 (1): 163.
- 1073
- 1074 Overbosch, Femke, Mark de Boer, Karin Ellen Veldkamp, Pauline Ellerbroek, Chantal P.
- 1075 Bleeker-Rovers, Bram Goorhuis, Michele van Vugt, et al. 2020. "Public Health Response
- 1076 to Two Imported, Epidemiologically Related Cases of Lassa Fever in the Netherlands
- 1077 (Ex Sierra Leone), November 2019." *Euro Surveillance: Bulletin Europeen Sur Les*
- 1078 *Maladies Transmissibles = European Communicable Disease Bulletin* 25 (15).
- 1079 <https://doi.org/10.2807/1560-7917.ES.2020.25.15.2000265>.
- 1080 Parashar, U. D., L. M. Sunn, F. Ong, A. W. Mounts, M. T. Arif, T. G. Ksiazek, M. A. Kamaluddin,
- 1081 et al. 2000. "Case-Control Study of Risk Factors for Human Infection with a New
- 1082 Zoonotic Paramyxovirus, Nipah Virus, during a 1998-1999 Outbreak of Severe
- 1083 Encephalitis in Malaysia." *The Journal of Infectious Diseases* 181 (5): 1755–59.
- 1084 Park, Sun Hee, Yeon-Sook Kim, Younghee Jung, Soo Young Choi, Nam-Hyuk Cho, Hye Won
- 1085 Jeong, Jung Yeon Heo, et al. 2016. "Outbreaks of Middle East Respiratory Syndrome in
- 1086 Two Hospitals Initiated by a Single Patient in Daejeon, South Korea." *Infection &*
- 1087 *Chemotherapy* 48 (2): 99–107.
- 1088 Pepin, Michel, Michele Bouloy, Brian H. Bird, Alan Kemp, and Janusz Paweska. 2010. "Rift
- 1089 Valley Fever Virus(Bunyaviridae: Phlebovirus): An Update on Pathogenesis, Molecular
- 1090 Epidemiology, Vectors, Diagnostics and Prevention." *Veterinary Research* 41 (6): 61.
- 1091 Poletto, C., C. Pelat, D. Levy-Bruhl, Y. Yazdanpanah, P. Y. Boelle, and V. Colizza. 2014.
- 1092 "Assessment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
- 1093 Epidemic in the Middle East and Risk of International Spread Using a Novel Maximum
- 1094 Likelihood Analysis Approach." *Euro Surveillance: Bulletin Europeen Sur Les Maladies*
- 1095 *Transmissibles = European Communicable Disease Bulletin* 19 (23).
- 1096 <https://doi.org/10.2807/1560-7917.es2014.19.23.20824>.
- 1097 "ProMED-Mail." n.d. Accessed December 31, 2020. <https://promedmail.org/>.
- 1098 Pulliam, Juliet R. C., Jonathan H. Epstein, Jonathan Dushoff, Sohayati A. Rahman, Michel
- 1099 Bunning, Aziz A. Jamaluddin, Alex D. Hyatt, et al. 2012. "Agricultural Intensification,
- 1100 Priming for Persistence and the Emergence of Nipah Virus: A Lethal Bat-Borne
- 1101 Zoonosis." *Journal of the Royal Society, Interface / the Royal Society* 9 (66): 89–101.
- 1102 Rahman, Muhammad Aziz, Mohammad Jahangir Hossain, Sharmin Sultana, Nusrat Homaira,
- 1103 Salah Uddin Khan, Mahmudur Rahman, Emily S. Gurley, et al. 2012. "Date Palm Sap
- 1104 Linked to Nipah Virus Outbreak in Bangladesh, 2008." *Vector Borne and Zoonotic*
- 1105 *Diseases* 12 (1): 65–72.
- 1106 Reeves, Tarian, Abdallah M. Samy, and A. Townsend Peterson. 2015. "MERS-CoV Geography
- 1107 and Ecology in the Middle East: Analyses of Reported Camel Exposures and a
- 1108 Preliminary Risk Map." *BMC Research Notes* 8 (1): 1–7.
- 1109 "Rift Valley Fever in Egypt and Other African Countries: Historical Review, Recent Outbreaks
- 1110 and Possibility of Disease Occurrence in Egypt." 2018. *Acta Tropica* 181 (May): 40–49.
- 1111 Roberts, Leslie. 2018. "Nigeria Hit by Unprecedented Lassa Fever Outbreak." *Science* 359
- 1112 (6381): 1201–2.
- 1113 Røttingen, John-Arne, Dimitrios Gouglas, Mark Feinberg, Stanley Plotkin, Krishnaswamy V.
- 1114 Raghavan, Andrew Witty, Ruxandra Draghia-Akli, Paul Stoffels, and Peter Piot. 2017.
- 1115 "New Vaccines against Epidemic Infectious Diseases." *The New England Journal of*

- 1116 *Medicine* 376 (7): 610–13.
- 1117 Saameli, René, Dikolela Kalubi, Mark Herringer, Tim Sutton, and Eric de Roodenbeke. 2018.
- 1118 “Healthsites.io: The Global Healthsites Mapping Project.” *Technologies for*
- 1119 *Development*. [https://doi.org/10.1007/978-3-319-91068-0\\_5](https://doi.org/10.1007/978-3-319-91068-0_5).
- 1120 Sabin, A. B., and R. W. Blumberg. 1947. “Human Infection with Rift Valley Fever Virus and
- 1121 Immunity Twelve Years after Single Attack.” *Proceedings of the Society for Experimental*
- 1122 *Biology and Medicine*. *Society for Experimental Biology and Medicine* 64 (4): 385–89.
- 1123 Sha, Jianping, Yuan Li, Xiaowen Chen, Yan Hu, Yajin Ren, Xingyi Geng, Zhiruo Zhang, and
- 1124 Shelan Liu. 2017. “Fatality Risks for Nosocomial Outbreaks of Middle East Respiratory
- 1125 Syndrome Coronavirus in the Middle East and South Korea.” *Archives of Virology* 162
- 1126 (1): 33–44.
- 1127 Sheahan, Timothy, Barry Rockx, Eric Donaldson, Amy Sims, Raymond Pickles, Davide Corti,
- 1128 and Ralph Baric. 2008. “Mechanisms of Zoonotic Severe Acute Respiratory Syndrome
- 1129 Coronavirus Host Range Expansion in Human Airway Epithelium.” *Journal of Virology* 82
- 1130 (5): 2274–85.
- 1131 Siddle, Katherine J., Philomena Eromon, Kayla G. Barnes, Samar Mehta, Judith U. Oguzie,
- 1132 Ikponmwoza Odi, Stephen F. Schaffner, et al. 2018. “Genomic Analysis of Lassa Virus
- 1133 during an Increase in Cases in Nigeria in 2018.” *The New England Journal of Medicine*
- 1134 379 (18): 1745–53.
- 1135 Sissoko, Daouda, Claude Giry, Philippe Gabrie, Arnaud Tarantola, François Pettinelli, Louis
- 1136 Collet, Eric D’Ortenzio, Philippe Renault, and Vincent Pierre. 2009. “Rift Valley Fever,
- 1137 Mayotte, 2007–2008.” *Emerging Infectious Diseases* 15 (4): 568.
- 1138 Smithburn, K. C., and A. F. Mahaffy. 1949. “Rift Valley Fever; Accidental Infections among
- 1139 Laboratory Workers.” *Journal of Immunology* 62 (2): 213–27.
- 1140 Sow, Abdourahmane, Ousmane Faye, Yamar Ba, Hampathé Ba, Diawo Diallo, Oumar Faye,
- 1141 Cheikh Loucoubar, et al. 2014. “Rift Valley Fever Outbreak, Southern Mauritania, 2012.”
- 1142 *Emerging Infectious Diseases* 20 (2): 296.
- 1143 Sow, Abdourahmane, Ousmane Faye, Yamar Ba, Diawo Diallo, Gamou Fall, Oumar Faye,
- 1144 Ndeye Sakha Bob, et al. 2016. “Widespread Rift Valley Fever Emergence in Senegal in
- 1145 2013–2014.” *Open Forum Infectious Diseases* 3 (3). <https://doi.org/10.1093/ofid/ofw149>.
- 1146 Tan, Kay-Sin, Chong Tin Tan, and Khean Jin Goh. 1999. “Epidemiological Aspects of Nipah
- 1147 Virus Infection.” *Neurol J Southeast Asia* 4 (1): 77–81.
- 1148 Tatem, Andrew J. 2017. “WorldPop, Open Data for Spatial Demography.” *Scientific Data* 4
- 1149 (January): 170004.
- 1150 Tindale, Lauren C., Jessica E. Stockdale, Michelle Coombe, Emma S. Garlock, Wing Yin Venus
- 1151 Lau, Manu Saraswat, Louxin Zhang, Dongxuan Chen, Jacco Wallinga, and Caroline
- 1152 Colijn. 2020. “Evidence for Transmission of COVID-19 Prior to Symptom Onset.” *ELife* 9
- 1153 (June). <https://doi.org/10.7554/eLife.57149>.
- 1154 Virlogeux, Victor, Minah Park, Joseph T. Wu, and Benjamin J. Cowling. 2016. “Association
- 1155 between Severity of MERS-CoV Infection and Incubation Period.” *Emerging Infectious*
- 1156 *Diseases* 22 (3): 526–28.
- 1157 WHO. 2016. “Prioritizing Diseases for Research and Development in Emergency Contexts.”
- 1158 2016. [https://www.who.int/activities/prioritizing-diseases-for-research-and-development-](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)
- 1159 [in-emergency-contexts](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts).
- 1160 ———. 2017a. “WHO Target Product Profile for Lassa Virus Vaccine.”
- 1161 [https://www.who.int/blueprint/priority-diseases/key-](https://www.who.int/blueprint/priority-diseases/key-action/LassaVirusVaccineTPP.PDF?ua=1)
- 1162 [action/LassaVirusVaccineTPP.PDF?ua=1](https://www.who.int/blueprint/priority-diseases/key-action/LassaVirusVaccineTPP.PDF?ua=1).
- 1163 ———. 2017b. “WHO Target Product Profile for Nipah Virus Vaccine.”
- 1164 [https://www.who.int/blueprint/priority-diseases/key-action/Nipah\\_virus\\_vaccineTPP.pdf](https://www.who.int/blueprint/priority-diseases/key-action/Nipah_virus_vaccineTPP.pdf).
- 1165 ———. 2017c. “WHO Target Product Profiles for MERS-CoV Vaccines.”
- 1166 <https://www.who.int/blueprint/what/research->



- 1167 development/MERS\_CoV\_TPP\_15052017.pdf?ua=1.  
1168 ———. 2018. “Weekly Bulletin on Outbreaks and Other Emergencies.” 2018.  
1169 <https://apps.who.int/iris/bitstream/handle/10665/273028/OEW27-300606072018.pdf>.  
1170 ———. 2019. “Target Product Profiles for Rift Valley Fever Virus Vaccines.”  
1171 [https://www.who.int/docs/default-source/blue-print/call-for-comments/tpv-rift-valley-fever-](https://www.who.int/docs/default-source/blue-print/call-for-comments/tpv-rift-valley-fever-vaccines-draft3-0pc.pdf?sfvrsn=f2f3b314_2)  
1172 [vaccines-draft3-0pc.pdf?sfvrsn=f2f3b314\\_2](https://www.who.int/docs/default-source/blue-print/call-for-comments/tpv-rift-valley-fever-vaccines-draft3-0pc.pdf?sfvrsn=f2f3b314_2).  
1173 ———. 2020. “WHO Coronavirus (COVID-19) Dashboard.” 2020. <https://covid19.who.int/>.  
1174 ———. n.d. “THE GLOBAL HEALTH OBSERVATORY.” Accessed March 12, 2021.  
1175 [https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-](https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/sdg-target-3.c-health-workforce)  
1176 [details/GHO/sdg-target-3.c-health-workforce](https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/sdg-target-3.c-health-workforce).  
1177 “WHO | Rift Valley Fever – Gambia.” 2018, February. [http://www.who.int/csr/don/26-february-](http://www.who.int/csr/don/26-february-2018-rift-valley-fever-gambia/en/)  
1178 [2018-rift-valley-fever-gambia/en/](http://www.who.int/csr/don/26-february-2018-rift-valley-fever-gambia/en/).  
1179 Wilson, M. L., L. E. Chapman, D. B. Hall, E. A. Dykstra, K. Ba, H. G. Zeller, M. Traore-  
1180 Lamizana, J. P. Hervy, K. J. Linthicum, and C. J. Peters. 1994. “Rift Valley Fever in  
1181 Rural Northern Senegal: Human Risk Factors and Potential Vectors.” *The American*  
1182 *Journal of Tropical Medicine and Hygiene* 50 (6): 663–75.  
1183 Woods, Christopher W., Adam M. Karpati, Thomas Grein, Noel McCarthy, Peter Gaturuku, Eric  
1184 Muchiri, Lee Dunster, et al. 2002. “An Outbreak of Rift Valley Fever in Northeastern  
1185 Kenya, 1997-98.” *Emerging Infectious Diseases* 8 (2): 138.  
1186 Yen, Catherine, Terri B. Hyde, Alejandro J. Costa, Katya Fernandez, John S. Tam, Stéphane  
1187 Hugonnet, Anne M. Huvos, Philippe Duclos, Vance J. Dietz, and Brenton T. Burkholder.  
1188 2015. “The Development of Global Vaccine Stockpiles.” *The Lancet Infectious Diseases*  
1189 15 (3): 340–47.  
1190 Yob, J. M., H. Field, A. M. Rashdi, C. Morrissy, B. van der Heide, P. Rota, A. bin Adzhar, et al.  
1191 2001. “Nipah Virus Infection in Bats (Order Chiroptera) in Peninsular Malaysia.”  
1192 *Emerging Infectious Diseases* 7 (3): 439–41.  
1193 Youssouf, Hassani, Marion Subiros, Genevieve Denetiere, Louis Collet, Laure Dommergues,  
1194 Amandine Pauvert, Patrick Rabarison, et al. 2020. “Rift Valley Fever Outbreak, Mayotte,  
1195 France, 2018–2019.” *Emerging Infectious Diseases* 26 (4): 769.  
1196

1197 **Supplementary Information**

1198

1199 **Table of Contents**

1200

1201 Table S1 ..... 35

1202 Figures S1-S4 ..... 36

1203 SI Text ..... 40

1204 1. Sensitivity analysis: Reactive vaccination strategies ..... 40

1205 2. Sensitivity analysis:  $R_0$  ..... 41

1206 3. Model limitations ..... 41


1207 Figures S5-S34 ..... 45

1208 **Table S1. Overview of data references.**


Parameter	LASV	MERS-CoV	NiV	RVFV
Case reports	1-11	11-15	11,16-22	11,23-43
Seasonality	See case reports	See case reports	See case reports	See case reports
Incubation period	44-47	48-51	52	53-60
Infectious period	47	48,51,61,62	63	64
R <sub>0</sub>	65	49, 66-70	52	

1209 1 (“Nigeria Centre for Disease Control” n.d.), 2 (Carey et al. 1972), 3 (Monath et al. 1973), 4 (Bowen et al.  
 1210 1975), 5 (E Keane 1977), 6 (ter Meulen et al. 2001), 7 (Ajayi 2013), 8 (Fisher-Hoch et al. 1995), 9 (Fraser  
 1211 et al. 1974), 10 (Hamblion et al. 2018), 11 (“ProMED-Mail” n.d.), 12 (“MERS-CoV Cases” n.d.), 13  
 1212 (“Ministry of Health - Kingdom of Saudi Arabia” 2020), 14 (Reeves, Samy, and Townsend Peterson  
 1213 2015), 15 <http://rambaut.github.io/MERS-Tools/cases2.html>, 16 (Hsu et al. 2004), 17 (Gurley,  
 1214 Montgomery, Hossain, Islam, et al. 2007), 18 (Kumar et al. 2019), 19 (Nikolay, Salje, Hossain, Khan,  
 1215 Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019), 20 (Tan, Tan, and Goh 1999),  
 1216 21 (Parashar et al. 2000), 22 (Chan et al. 2002a), 23 (“Rift Valley Fever in Egypt and Other African  
 1217 Countries: Historical Review, Recent Outbreaks and Possibility of Disease Occurrence in Egypt” 2018),  
 1218 24 (Laughlin et al. 1979), 25 (“WHO | Rift Valley Fever – Gambia” 2018), 26 (Centers for Disease Control  
 1219 and Prevention (CDC) 1998), 27 (Woods et al. 2002), 28 (Centers for Disease Control and Prevention  
 1220 (CDC) 2007), 29 (Jouan et al. 1988), 30 (Faye et al. 2007), 21 (Sow et al. 2014), 32 (Bob et al. 2017), 33  
 1221 (Sissoko et al. 2009), 34 (Métras et al. 2016), 35 (Youssof et al. 2020), 36 (Centers for Disease Control  
 1222 and Prevention (CDC) 2020), 37 (FAO 2017), 38 (Ahmad 2000), 39 (Sow et al. 2016), 40 (Centers for  
 1223 Disease Control and Prevention (CDC) 1998), 41 (Nderitu et al. 2010), 42 (WHO 2018), 43 (Archer et al.  
 1224 2013), 44 (Frame et al. 1970), 45 (Monath 1974), 46 (Myne et al. 2015), 47 (Khan et al. 2008), 48 (Assiri,  
 1225 Al-Tawfiq, et al. 2013), 49 (Cauchemez et al. 2014), 50 (Virlogeux et al. 2016), 51 (Sha et al. 2017), 52  
 1226 (Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al.  
 1227 2019), 53 (Daubney, Hudson, and Garnham 1931), 54 (Francis and Magill 1935), 55 (Kitchen 1934), 56  
 1228 (Findlay 1932), 57 (Sabin and Blumberg 1947), 58 (Smithburn and Mahaffy 1949), 59 (Mundel and Gear  
 1229 1951), 60 (Hoogstraal et al. 1979), 61 (Ki 2015), 62 (Park et al. 2016), 63 (Gurley, Montgomery, Hossain,  
 1230 Bell, et al. 2007), 64 (Bird et al. 2009), 65 (Lo Iacono et al. 2015), 66 (Brebán, Riou, and Fontanet 2013),  
 1231 67 (Poletto et al. 2014), 68 (Chowell et al. 2014), 69 (Kucharski and Althaus 2015), 70 (Cauchemez et al.  
 1232 2016)


1233  
 1234  
 1235  
 1236  
 1237




1240 **Figure S1. Spillover and reactive vaccination patterns for Lassa fever virus (LASV).** (A)  
1241 Observed weekly Lassa fever spillover cases (grey bars) and estimated seasonal spillover rate  
1242 (red line). (B) Annual number of spillovers over the past 5 years (red) and cumulative  
1243 distribution of simulated annual spillovers from 1000 replicates (grey). (C) Median weekly  
1244 simulated spillover and human-to-human Lassa fever cases. (D) Average weekly number of  
1245 reactive campaigns triggered via spillover detection compared to the estimated seasonal  
1246 spillover rate (red line).



1248 **Figure S2. Spillover and reactive vaccination patterns for Middle Eastern respiratory**  
1249 **virus (MERS-CoV).** (A) Observed weekly MERS spillover cases (grey bars) and estimated  
1250 seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red)  
1251 and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C)  
1252 Median weekly simulated spillover and human-to-human MERS cases. (D) Average weekly  
1253 number of reactive campaigns triggered via spillover detection compared to the estimated  
1254 seasonal spillover rate (red line).



1256 **Figure S3. Spillover and reactive vaccination patterns for Nipah virus (NiV).** (A) Observed  
1257 weekly Nipah spillover cases (grey bars) and estimated seasonal spillover rate (red line). (B)  
1258 Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated  
1259 annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and  
1260 human-to-human Nipah cases. (D) Average weekly number of reactive campaigns triggered via  
1261 spillover detection compared to the estimated seasonal spillover rate (red line).



1263 **Figure S4. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV).**  
1264 (A) Observed monthly RVF spillover cases by region. (B) Annual number of spillovers over the  
1265 past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000  
1266 replicates (grey). (C) Median weekly simulated spillover and human-to-human RVF cases. (D)  
1267 Average weekly number of reactive campaigns triggered via spillover detection. Fitted  
1268 seasonality is not shown for RVFV as it was for the other pathogens because seasonality was fit  
1269 separately for each region.

1270 **SI Text.**

1271

1272 **1. Sensitivity analysis: Analysis of reactive vaccination scenarios**

1273

1274 In addition to our baseline reactive vaccination scenario, we examined the sensitivity of  
1275 vaccination impact to varying different scenario parameters: the threshold number of cases  
1276 needed to trigger a response, vaccination coverage in the general population, vaccination  
1277 coverage of healthcare workers (HCWs), time from the threshold trigger to the start of  
1278 vaccination, vaccine per exposure protection for one or two doses (PEP), and time delay from  
1279 vaccination to protection (see Table 2 for default, low, and high parameter values). In addition,  
1280 we examined the sensitivity of model results to the assumed or estimated value of  $R_0$  for each  
1281 pathogen (SI Text section 2), and the impact of defining different catchment areas for  
1282 vaccination (SI Text section 3). The results of the sensitivity analysis for MERS-CoV are  
1283 summarized in the main text (Figure 6).

1284

1285 As expected, lowering the number of cases required to trigger a reactive vaccination campaign  
1286 or increasing the percent of the population targeted for vaccination increased the number of  
1287 vaccine regimens required for each pathogen (Figures S5-S8). These parameter values had a  
1288 similar impact on the number of vaccine regimens needed to vaccinate HCWs (Figures S9-  
1289 S12). Higher  $R_0$  values also increased the required number of vaccine regimens needed as  
1290 higher human-to-human transmission increased the likelihood of the case threshold being  
1291 exceeded. However, this impact was fairly small for LASV and RVFV due to their low  $R_0$  values  
1292 (Figures S5,S8).

1293

1294 When vaccination impact was measured as the fraction of cases averted, the largest impact for  
1295 each pathogen was achieved by lowering the threshold number of cases needed to trigger a  
1296 reactive vaccination campaign (Figures 4A, S13A-15A). The second largest impact on the  
1297 fraction of cases averted for each pathogen besides RVFV was achieved by decreasing the  
1298 delay between a campaign being triggered and the start of vaccination (Figures 4A, S13A-  
1299 S14A). For RVFV, the 2nd largest fraction of cases could be averted by increasing vaccination  
1300 coverage in the general population or increasing vaccine PEP for a single dose vaccine (Figure  
1301 S15A). Although lowering the response threshold maximized the fraction of cases averted for  
1302 each pathogen, it did not maximize the number of cases averted per vaccine regimen  
1303 administered, because lowering the threshold increased the number of vaccine campaigns and  
1304 the required number of vaccine regimens (Figures S5-S8, 4B, S13B-S15B). For LASV, the  
1305 largest per regimen impact was achieved by minimizing the delay prior to vaccination (Figure  
1306 S13B). For NiV and RVFV, the largest per regimen impact was achieved by raising the  
1307 response threshold (Figures S14B-S15B).

1308

1309 For each pathogen (besides RVFV, which is not associated with nosocomial transmission)  
1310 vaccinating HCWs had a larger per regimen impact than vaccinating the general population  
1311 (Figures 4C, S13C-S14C). Reducing the delay prior to vaccination and increasing vaccine PEP  
1312 had the largest impact on the number of cases averted per HCW vaccinated (Figures 4C, S13C-  
1313 S14C). The number of cases averted was slightly lower under our high-coverage of HCWs



1314 scenario because the high coverage of vaccination among HCWs was paired with low coverage  
1315 among the general population (Figures 4A, S13A-S15A). However, this scenario would have  
1316 achieved the highest number of cases averted per total number of vaccine regimens  
1317 administered for LASV, MERS-CoV, and NiV.

1318

## 1319 **2. Sensitivity analysis: Impact of $R_0$**

1320

1321 All  $R_0$  values and uncertainty ranges used in our analysis were either drawn from the literature  
1322 or estimated from data (see Table 1 for parameter values and data sources). However,  $R_0$   
1323 estimates vary between studies and can also vary in space or time due to different  
1324 environmental conditions or differences in human contact networks. Therefore, we also tested  
1325 the sensitivity of our model results to lower and higher  $R_0$  values for each pathogen (for RVFV,  
1326 the default  $R_0=0$ , so only sensitivity to a higher value was examined). The number of total cases  
1327 increased with  $R_0$  for each pathogen, with the largest sensitivity observed for MERS-CoV  
1328 because the high estimate of  $R_0$  was close to 1 (Figure S16). There was also a large increase in  
1329 the number of vaccine regimens required to vaccinate either the general population or HCWs for  
1330 MERS-CoV at the higher  $R_0$  value, but the impact of  $R_0$  on the required number of vaccine  
1331 regimens was minimal for the other pathogens (Figures S17-S18). As a result, there were  
1332 minimal differences in the impact of vaccination under higher or lower  $R_0$  values for LASV, NiV,  
1333 or RVFV (Figures S19-S22). Vaccination averted both a greater magnitude and a higher fraction  
1334 of MERS cases as  $R_0$  increased (Figures S19-S20). In addition, the number of MERS cases  
1335 averted per vaccine regimen administered to the general population or to HCWs also increased  
1336 as  $R_0$  increased (Figures S21-S22). These results highlight the increasing potential  
1337 effectiveness for reactive vaccination as a control strategy as  $R_0$  approaches 1 and larger  
1338 outbreaks become more likely.

1339

## 1340 **3. Model limitations**

1341

1342 The goal of our analysis was to estimate vaccine stockpile needs and identify the most  
1343 important determinants of success for reactive vaccination of zoonotic emerging pathogens. We  
1344 modeled several different reactive vaccination strategies that are applicable to any zoonotic  
1345 emerging pathogen, and tested this framework for four pathogens with differing epidemiologies.  
1346 In addition, we explored the sensitivity of our results to different aspects of reactive vaccine  
1347 deployment, such as the coverage level, deployment delays, and vaccine per exposure  
1348 protection. However, there are some limitations to our approach that could affect these  
1349 estimates.

1350

1351 First, we have a relatively poor understanding of the epidemiology of most emerging zoonotic  
1352 pathogens, and data that could be used to try and elucidate the most important aspects of their  
1353 epidemiologies is limited. Here we examined the impact of reactive vaccination for four  
1354 pathogens with differing epidemiologies to try and capture how a range of epidemiological  
1355 parameters (e.g., spillover rates,  $R_0$ , etc.) affect vaccine stockpile requirements and the likely  
1356 impact of vaccination. But there are still uncertainties surrounding the epidemiology of these  
1357 pathogens that could affect the results of our analysis, such as the frequency of human-to-

1358 human transmission of MERS-CoV in community settings (Group and The WHO MERS-CoV  
1359 Research Group 2013), or the route of NiV spillover to humans during recent outbreaks in India  
1360 (Arunkumar et al. 2019). In addition, because no vaccines have been licensed for these  
1361 pathogens yet, we had to make assumptions about key vaccine parameters (e.g., number of  
1362 doses, time between vaccination and protection, and per exposure protection), based on the  
1363 current vaccine target product profiles (TPPs) for each pathogen. We also had to make  
1364 assumptions about the baseline reactive vaccination campaign parameter estimates such as  
1365 campaign response time and duration (and best-case and worst-case scenarios for our  
1366 sensitivity analysis). Assessing vaccine stockpile needs for newly emerged pathogens will  
1367 involve even more uncertainty as epidemiological knowledge is critically limited immediately  
1368 following emergence, as was demonstrated following the 2019 emergence of SARS-CoV-2 (Lee  
1369 et al. 2020; Tindale et al. 2020). Our modeling approach can be applied to newly emerged  
1370 zoonotic pathogens, but there will likely be a large amount of uncertainty regarding vaccine  
1371 stockpile needs and where vaccination campaigns are most likely to occur.

1372

1373 A second, related, limitation, is that the modeling framework is intended to be applicable for a  
1374 range of emerging zoonotic pathogens, and therefore cannot incorporate all of the specific  
1375 epidemiological details that might affect vaccine demand or impact for a particular pathogen.

1376

1377 Third, we only considered reported cases when estimating pathogen spillover rates and human-  
1378 to-human transmission because undiagnosed or unreported infections would not trigger an  
1379 outbreak response. For several of the pathogens considered, however, the majority of  
1380 infections--and even symptomatic cases--go unreported. A frequently cited study estimated that  
1381 LASV infects 100,000-300,000 and kills 5,000 people annually (McCormick et al. 1987), and  
1382 seroprevalence studies in several endemic areas indicate that spillover occurs much more  
1383 frequently than reported (Kernéis et al. 2009; O'Hearn et al. 2016; Gibb et al. 2017).

1384 Seroprevalence surveys for RVFV and MERS-CoV also indicate that these pathogens cause  
1385 many unreported infections in at least some subpopulations (Müller et al. 2015; Munyua et al.  
1386 2021; Bron et al. 2021). Therefore, our estimate of reactive vaccination impact does not take  
1387 into account the potential reduction in unobserved cases that would occur if at-risk populations  
1388 were vaccinated. Improved surveillance could address this issue and would likely increase the  
1389 frequency of reactive vaccination campaigns. This detection issue could also be partially  
1390 addressed by adjusting the case threshold for outbreak response to account for the case  
1391 detection probability, and then also adjusting vaccination impact to account for undetected  
1392 infections.

1393

1394 Next, because the extent of community transmission for each of the study pathogens is poorly  
1395 understood, we assumed that human-to-human transmission was limited to nosocomial  
1396 settings. Although this could result in an underestimate of vaccine demand, our model  
1397 simulations are consistent with epidemiological patterns observed to date (Figures S1-S4). We  
1398 also assumed that all nosocomial transmission involved transmission from patient to HCWs or  
1399 between HCWs and that there was no patient-to-patient or HCW-to-patient transmission.

1400 Therefore our estimates of the impact of vaccinating HCWs represents the upper-bound on the


1401 effectiveness of this strategy as instances of patient-to-patient transmission would not be  
1402 prevented via this strategy.

1403  
1404 Another simplifying assumption of our model is that cases in one catchment area do not lead to  
1405 transmission or an outbreak outside of that catchment area. However, imported cases of these  
1406 pathogens have been reported. A MERS-CoV outbreak in South Korea derived from a spillover  
1407 event in the Middle East (Park et al. 2016), a NiV outbreak in Singapore derived from a spillover  
1408 event in Malaysia (Chan et al. 2002b), and cases of Lassa fever have been imported to Europe  
1409 (Overbosch et al. 2020). These types of events have been rare, and none of these documented  
1410 events resulted in an outbreak larger than the range of those that we simulated. Furthermore,  
1411 documented outbreaks involving pathogen spread to neighbouring catchment areas are  
1412 included in our datasets, and as such are to some extent captured in the current analysis. For  
1413 example, our datasets include Lassa fever cases in Benin derived from an outbreak in the  
1414 neighbouring adm2 located in Nigeria and RVFV outbreaks within multiple catchment areas of  
1415 Tanzania that likely resulted from the movement of livestock (“ProMED-Mail” n.d.; Bron et al.  
1416 2021). Therefore, our model already implicitly incorporates the possibility of spread between-  
1417 catchment areas, and although our model does not predict spillover cases occurring outside of  
1418 each pathogen’s currently documented geographic distribution, the reactive vaccination  
1419 strategies we examined should also be applicable for responding to imported cases and their  
1420 associated outbreaks.


1421  
1422 Another limitation is that we had to make several simplifying assumptions regarding the  
1423 implementation of the reactive vaccination campaigns. One such simplification was assuming  
1424 that all vaccine doses (per regimen) were administered on the same day. This is likely an  
1425 unrealistic assumption for mass vaccination campaigns, particularly those that cover large  
1426 geographic areas. Relaxing this assumption would reduce the public health impact of reactive  
1427 vaccination in the same manner that delays in the start of the vaccination campaign did in our  
1428 analysis. Another simplification is that we did not consider any targeted vaccination strategies  
1429 besides targeting healthcare workers to limit nosocomial outbreaks or ring vaccination around  
1430 index cases. For the ring vaccination we calculated the number of index cases that would trigger  
1431 a ring vaccination response, but we did not model the impact of this response. Besides these  
1432 two strategies, there might be other targeted vaccination approaches that would require a  
1433 smaller vaccine stockpile than targeting the general population while still producing a substantial  
1434 public health impact. For example, in the case of RVFV, a potential vaccination strategy might  
1435 include targeting high-risk groups such as veterinarians, butchers, and livestock holders. One  
1436 reason we did not consider this strategy is because of the coarseness or absence of the data  
1437 available on these professions. While veterinarians only constitute a small proportion of the at-  
1438 risk population, their higher risk of acquiring infections could increase the impact of a campaign  
1439 that targeted them for vaccination. This could also increase the safety of those that are often at  
1440 the frontline of an outbreak response. Similar targeted strategies might be envisioned for camel  
1441 workers in areas where MERS-CoV is endemic in livestock, or individuals who collect or  
1442 consume date palm sap in India and Bangladesh (Dudas et al. 2018; Islam et al. 2016).

1443

1444 Finally, spillover cases were distributed over catchment areas representing 2nd administrative  
1445 districts (or hospitals within the 1st administrative units in our sensitivity analysis), irrespective of  
1446 the urban/rural nature of the catchment area. This may result in an overestimation of the  
1447 population at risk and thus the number of regimens needed. Simulating the spillover rates per  
1448 2nd administrative unit, instead of at the 1st administrative level, could improve the estimation of  
1449 reactive vaccine demand. However, the adm2 location of spillover cases were not available  
1450 most of the time.  
1451  
1452  
1453




1455 **Figure S5. Vaccine regimens required for Lassa fever virus (LASV).** The impact of varying  
1456 several model parameters on the number of vaccine regimens required to meet reactive  
1457 vaccination campaign targets. Base refers to the default scenario used in our main analysis.  
1458 See Table 2 for specific parameter values.  
1459  
1460




1462 **Figure S6. Vaccine regimens required for Middle Eastern respiratory virus (MERS-CoV).**  
1463 The impact of varying several model parameters on the number of vaccine regimens required to  
1464 meet reactive vaccination campaign targets. Base refers to the default scenario used in our  
1465 main analysis. See Table 2 for specific parameter values.

1466




1468 **Figure S7. Vaccine regimens required for Nipah virus (NiV).** The impact of varying several  
1469 model parameters on the number of vaccine regimens required to meet reactive vaccination  
1470 campaign targets. Base refers to the default scenario used in our main analysis. See Table 2 for  
1471 specific parameter values.




1473 **Figure S8. Vaccine regimens required for Rift Valley fever virus (RVFV).** The impact of  
1474 varying several model parameters on the number of vaccine regimens required to meet reactive  
1475 vaccination campaign targets. Base refers to the default scenario used in our main analysis.  
1476 See Table 2 for specific parameter values.







1478 **Figure S9. Vaccine regimens required to vaccinate healthcare workers for Lassa fever**  
1479 **virus (LASV).** The impact of varying several model parameters on the number of vaccine  
1480 regimens required to meet reactive vaccination campaign targets among healthcare workers  
1481 (HCWs). Base refers to the default scenario used in our main analysis. See Table 2 for specific  
1482 parameter values.




1484 **Figure S10. Vaccine regimens required to vaccinate healthcare workers for Middle**  
1485 **Eastern respiratory virus (MERS-CoV).** The impact of varying several model parameters on  
1486 the number of vaccine regimens required to meet reactive vaccination campaign targets among  
1487 healthcare workers (HCWs). Base refers to the default scenario used in our main analysis. See  
1488 Table 2 for specific parameter values.




1490 **Figure S11. Vaccine regimens required to vaccinate healthcare workers for Nipah virus**  
1491 **(NiV).** The impact of varying several model parameters on the number of vaccine regimens  
1492 required to meet reactive vaccination campaign targets among healthcare workers (HCWs).  
1493 Base refers to the default scenario used in our main analysis. See Table 2 for specific  
1494 parameter values.




1496 **Figure S12. Vaccine regimens required to vaccinate veterinarians for Rift Valley fever**  
1497 **virus (RVFV).** The impact of varying several model parameters on the number of vaccine  
1498 regimens required to meet reactive vaccination campaign targets among veterinarians (HCWs).  
1499 Base refers to the default scenario used in our main analysis. See Table 2 for specific  
1500 parameter values.



1502 **Figure S13. Vaccination impact sensitivity analysis for LASV.** Sensitivity of vaccination  
 1503 impact for LASV to variation in different campaign parameters expressed as (A) fraction of  
 1504 cases averted, (B) cases averted per 100,000 vaccinated in the general population, and (C)  
 1505 cases averted per 1,000 health care workers (HCWs) vaccinated.




1507 **Figure S14. Vaccination impact sensitivity analysis for NiV.** Sensitivity of vaccination impact  
 1508 for NiV to variation in different campaign parameters expressed as (A) fraction of cases averted,  
 1509 (B) cases averted per 100,000 vaccinated in the general population, and (C) cases averted per  
 1510 1,000 health care workers (HCWs) vaccinated.




1512 **Figure S15. Vaccination impact sensitivity analysis for RVFV.** Sensitivity of vaccination  
1513 impact for RVFV to variation in different campaign parameters expressed as (A) fraction of  
1514 cases averted, (B) cases averted per 100,000 vaccinated in the general population, and (C)  
1515 cases averted per 1,000 health care workers (HCWs) vaccinated.

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/) .




1517 **Figure S16. Number of cases under different  $R_0$  assumptions.**







1519 **Figure S17. Number of vaccine regimens required under different R<sub>0</sub> assumptions.**




1521 **Figure S18. Number of vaccine regimens required for healthcare workers (HCWs) under**  
1522 **different  $R_0$  assumptions.**




1524 **Figure S19. Number of cases averted by vaccinating the general population under**  
1525 **different R<sub>0</sub> assumptions.**  
1526



1528 **Figure S20. Fraction of cases averted by vaccinating the general population under**  
1529 **different  $R_0$  assumptions.**  
1530



1532 **Figure S21. Number of cases averted per vaccine regimen administered to the general**  
1533 **population under different  $R_0$  assumptions.**  
1534



1536 **Figure S22. Number of cases averted per vaccine regimen administered to healthcare**  
1537 **workers (HCWs) under different  $R_0$  assumptions.**

### 1538 3. Analysis of different spillover and vaccination catchment areas

1539

1540 In our analysis we estimated spillover rates for each pathogen at the 1st administrative level  
1541 (adm1). We then accounted for spatial clustering of cases below the adm1 level by associating  
1542 each simulated case with a catchment area. In the main analysis, catchment areas were defined  
1543 as the 2nd administrative units (adm2) within each adm1. For countries with no 2nd  
1544 administrative level, hospitals within an adm1 were treated as catchment areas (hospitals within  
1545 10 km were combined into a single catchment area). This catchment area definition produced  
1546 1570 catchment areas for LASV, 767 for MERS-CoV, 5076 for NiV and 2126 for RVFV. Here we  
1547 consider two alternative catchment area definitions: (1) treating all adm1 units as unique  
1548 catchment areas, and (2) treating all hospitals within adm1 units as unique catchment areas  
1549 (with hospitals <10km apart combined into a single catchment area). The adm1 catchment area  
1550 definition resulted in 214 catchment areas for LASV, 82 for MERS-CoV, 375 for NiV and 343 for  
1551 RVFV. The adm1 hospitals catchment area definition produced 1749 catchment areas for  
1552 LASV, 3138 for MERS-CoV, 10799 for NiV and 4722 for RVFV. Therefore the adm1 catchment  
1553 areas are larger than the adm2 catchment areas, while the adm1 hospitals catchment areas are  
1554 generally smaller than the adm2 catchment areas. Because spillover rates were estimated at  
1555 the adm1 level, spillovers within an adm1 unit were allocated via a multinomial distribution to all  
1556 hospital catchment areas within that adm1 unit, with a probability of  $1/(\# \text{ of catchment areas}$   
1557  $\text{ within adm1})$ .

1558

1559 The number of spillover cases remained the same under the different catchment area  
1560 definitions, but the frequency, timing, and location of reactive vaccination campaigns were  
1561 shifted. Reactive vaccination campaigns tended to be triggered sooner during the transmission  
1562 season for adm1 catchment areas because these catchment areas covered a broader area and  
1563 larger population (Figures S23-S26). There were only minor differences in the timing of  
1564 vaccination campaigns between the adm2 and adm1 hospitals catchment areas (Figures S1-S4,  
1565 S27-S30). The geographic distribution of spillovers was less clustered for the larger adm1  
1566 catchment areas, but more finely distributed and clustered for the adm1 hospital catchment  
1567 areas, particularly in countries like South Africa and Madagascar with large 1st-level  
1568 administrative regions (Figures 2A, S31A-S32A). A similar geographic pattern was observed for  
1569 the location of reactive vaccination campaigns (Figures 2B, S31B-S32B).

1570

1571 The total number of human-to-human cases did not differ by catchment area definition for any of  
1572 the pathogens (Figures 1A, S33A-S34A). The median number of reactive vaccination  
1573 campaigns was lower using adm1 catchment areas than adm2 catchment areas for MERS-CoV  
1574 (3; 95% PrI: 1-6 vs. 4; 95% PrI: 0-11) and RVFV (3; 95% PrI: 0-6 vs. 5; 95% PrI: 0-20) (Figures  
1575 1B, S33B). In contrast, the median number of reactive vaccination campaigns were higher using  
1576 adm1 catchment areas for LASV (3; 95% PrI: 1-6 vs. 0; 95% PrI: 0-20) and NiV (1; 95% PrI: 0-3  
1577 vs. 0; 95% PrI: 0-8). The frequency of years with no reactive vaccination campaigns was lower  
1578 using adm1 catchment areas compared to adm2 or adm1 hospital catchment areas for all four  
1579 pathogens. Both the median number of reactive vaccination campaigns and the frequency of  
1580 years with no campaigns were similar using adm1 hospital catchment areas compared to the

1581 baseline adm2 catchment areas, although the frequency of years with no campaigns was  
1582 slightly higher for the adm1 hospital catchment areas for all four pathogens (Figures 1B, 34B).


1583  
1584 The number of vaccine regimens required to cover the general population were significantly  
1585 higher using adm1 catchment areas versus adm2 or adm1 hospital catchment areas for  
1586 (Figures 1C, S33C-34C). For MERS-CoV, the median required number of regimens increased  
1587 from 286,259 (95% PrI: 0-855,099) for adm1 hospital catchment areas, to 1,242,922 (95% PrI:  
1588 0-4,062,010) for adm2 catchment areas, and 14,303,325 (95% PrI: 1,416,969) for adm1  
1589 catchment areas. For LASV, the median required number of regimens increased from 0 (95%  
1590 PrI: 0-4,452,966) for adm1 hospital catchment areas and 0 (95% PrI: 0-5,184,360) for adm2  
1591 catchment areas, to 11,603,802 (95% PrI: 2,953,628-25,277,594) for adm1 catchment areas.  
1592 The number of vaccine regimens needed to vaccinate healthcare workers (HCWs) was also  
1593 lowest for adm1 hospital catchment areas and highest for adm1 catchment areas (Figures 1C,  
1594 S33C-S34C).

1595  
1596 The total number of cases averted via vaccination for each pathogen was also lowest using  
1597 adm1 hospital catchment areas and highest using adm1 catchment areas (Figures 1D, S33D-  
1598 S34D). For MERS, the median number of cases averted increased from 2 (95% PrI: 0-60) for  
1599 adm1 hospital catchment areas, to 6 (95% PrI: 0-83) for adm2 catchment areas, and 77 (95%  
1600 PrI: 0-342) for adm1 catchment areas. For Lassa fever, the median number of cases averted  
1601 increased from 0 (95% PrI: 0-306) for adm1 hospital catchment areas and 0 (95% PrI: 0-357) for  
1602 adm2 catchment areas, to 101 (95% PrI: 3-771) for adm1 catchment areas. For RVF, the  
1603 median number of cases averted increased from 29 (95% PrI: 0-3,525) for adm1 hospital  
1604 catchment areas, to 43 (95% PrI: 0-5,826) for adm2 catchment areas, and 66 (95% PrI: 0-  
1605 2,451) for adm1 catchment areas. For Nipah, the median number of cases averted was 0 for  
1606 each catchment area definition, but the mean was highest for adm1 catchment areas. The total  
1607 number of cases averted via vaccination of HCWs was also lowest using adm1 hospital  
1608 catchment areas and highest using adm1 catchment areas (Figures 1D, S33D-S34D). For  
1609 example, for MERS, the median number of nosocomial cases averted increased from 1 (95%  
1610 PrI: 0-60) for adm1 hospital catchment areas, to 4 (95% PrI: 0-77) for adm2 catchment areas,  
1611 and 55 (95% PrI: 0-259) for adm1 catchment areas.


1612  
1613 Although the number of cases averted via reactive vaccination was highest using adm1  
1614 catchment areas, the number of cases averted per vaccine regimen administered was not  
1615 necessarily the highest under this scenario because the number of regimens required was also  
1616 higher using adm1 catchment areas. For MERS, the highest per regimen impact was achieved  
1617 using adm1 hospital catchment areas where a median of 0.75 (95% PrI: 0-18.10) cases were  
1618 averted per 100,000 vaccine regimens administered. In comparison, a median of 0.58 (95% PrI:  
1619 0.02-2.58) cases were averted per 100,000 vaccine regimens administered in adm1 hospital  
1620 catchment areas, and 0.49 (95% PrI: 0-5.21) cases were averted per 100,000 vaccine regimens  
1621 administered in adm2 catchment areas. The highest per regimen impact for RVF was also  
1622 achieved using adm1 hospital catchment areas, with a median of 3.18 cases averted per  
1623 100,000 vaccine regimens administered versus 2.86 (95% PrI: 0-349.78) using adm2 catchment  
1624 areas or 1.69 (95% PrI: 0-68.42) using adm1 catchment areas. For Lassa fever the per regimen




1625 impact was relatively consistent across different catchment areas, and for Nipah the median  
1626 impact per 100,000 vaccine regimens administered was 0 for adm2 or adm1 hospital catchment  
1627 areas and 0.01 (95% PrI: 0-11.17) for adm1 catchment areas. For MERS and Lassa fever, the  
1628 largest impact of vaccinating HCWs as measured on a per-regimen-administered basis, was  
1629 also achieved using adm1 hospital catchment areas. The per-regimen impact of vaccinating  
1630 HCWs was minimal for Nipah, just as it was for vaccinating the general population (although the  
1631 estimated per-regimen impact of vaccinating HCWs was higher than the impact of vaccinating  
1632 the general population).  
1633




1635 **Figure S23. Spillover and reactive vaccination patterns for Lassa fever virus (LASV)**  
1636 **within adm1 catchment areas.** (A) Observed weekly Lassa fever spillover cases (grey bars)  
1637 and estimated seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5  
1638 years (red) and cumulative distribution of simulated annual spillovers from 1000 replicates  
1639 (grey). (C) Median weekly simulated spillover and human-to-human Lassa fever cases. (D)  
1640 Average weekly number of reactive campaigns triggered via spillover detection compared to the  
1641 estimated seasonal spillover rate (red line).  
1642




1644 **Figure S24. Spillover and reactive vaccination patterns for Middle Eastern respiratory**  
1645 **virus (MERS-CoV) within adm1 catchment areas.** (A) Observed weekly MERS spillover  
1646 cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of  
1647 spillovers over the past 5 years (red) and cumulative distribution of simulated annual spillovers  
1648 from 1000 replicates (grey). (C) Median weekly simulated spillover and human-to-human MERS  
1649 cases. (D) Average weekly number of reactive campaigns triggered via spillover detection  
1650 compared to the estimated seasonal spillover rate (red line).  
1651




1653 **Figure S25. Spillover and reactive vaccination patterns for Nipah virus (NiV) within adm1**  
1654 **catchment areas.** (A) Observed weekly Nipah spillover cases (grey bars) and estimated  
1655 seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red)  
1656 and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C)  
1657 Median weekly simulated spillover and human-to-human Nipah cases. (D) Average weekly  
1658 number of reactive campaigns triggered via spillover detection compared to the estimated  
1659 seasonal spillover rate (red line).  
1660




1662 **Figure S26. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV)**  
1663 **within adm1 catchment areas.** (A) Observed monthly RVFV spillover cases by region. (B)  
1664 Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated  
1665 annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and  
1666 human-to-human RVFV cases. (D) Average weekly number of reactive campaigns triggered via  
1667 spillover detection compared to the estimated seasonal spillover rate (red line).  
1668



1670 **Figure S27. Spillover and reactive vaccination patterns for Lassa fever virus (LASV)**  
1671 **within adm1 hospital catchment areas.** (A) Observed weekly Lassa fever spillover cases  
1672 (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of spillovers  
1673 over the past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000  
1674 replicates (grey). (C) Median weekly simulated spillover and human-to-human Lassa fever  
1675 cases. (D) Average weekly number of reactive campaigns triggered via spillover detection  
1676 compared to the estimated seasonal spillover rate (red line).  
1677




1679 **Figure S28. Spillover and reactive vaccination patterns for Middle Eastern respiratory**  
1680 **virus (MERS-CoV) within adm1 hospital catchment areas.** (A) Observed weekly MERS  
1681 spillover cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number  
1682 of spillovers over the past 5 years (red) and cumulative distribution of simulated annual  
1683 spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and human-to-  
1684 human MERS cases. (D) Average weekly number of reactive campaigns triggered via spillover  
1685 detection compared to the estimated seasonal spillover rate (red line).  
1686




1688 **Figure S29. Spillover and reactive vaccination patterns for Nipah virus (NiV) within adm1**  
1689 **hospital catchment areas.** (A) Observed weekly Nipah spillover cases (grey bars) and  
1690 estimated seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5  
1691 years (red) and cumulative distribution of simulated annual spillovers from 1000 replicates  
1692 (grey). (C) Median weekly simulated spillover and human-to-human Nipah cases. (D) Average  
1693 weekly number of reactive campaigns triggered via spillover detection compared to the  
1694 estimated seasonal spillover rate (red line).  
1695






1697 **Figure S30. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV)**  
1698 **within adm1 hospital catchment areas.** (A) Observed monthly RVF spillover cases by region.  
1699 (B) Annual number of spillovers over the past 5 years (red) and cumulative distribution of  
1700 simulated annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover  
1701 and human-to-human RVF cases. (D) Average weekly number of reactive campaigns triggered  
1702 via spillover detection compared to the estimated seasonal spillover rate (red line).  
1703




1706 **Figure S31. Geographic distribution of spillover cases and reactive vaccination**  
1707 **campaigns for adm1 catchment areas. (A) Geographic distribution of the expected annual**  
1708 **number of spillover cases for each pathogen. (B) Proportion of time a campaign will be**  
1709 **triggered.**




1712 **Figure S32. Geographic distribution of spillover cases and reactive vaccination**  
1713 **campaigns for adm1 hospital catchment areas. (A) Geographic distribution of the expected**  
1714 **annual number of spillover cases for each pathogen. (B) Proportion of time a campaign will be**  
1715 **triggered.**

It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/) .



1717 **Figure S33. Annual cases and reactive vaccination impacts for adm1 catchment areas.**  
1718 (A) Annual number of spillover, human-to-human (H2H), and total cases for each pathogen  
1719 across the entire study region. (B) Annual number of vaccine campaigns that will be triggered  
1720 due to the outbreak threshold. (C) Number of vaccine regimens required per year for outbreak  
1721 response when either the general population or healthcare workers (HCWs) only are targeted.  
1722 (D) Annual number of cases averted via vaccination.  
1723



1725 **Figure S34. Annual cases and reactive vaccination impacts for adm1 hospital-based**  
1726 **catchment areas.** (A) Annual number of spillover, human-to-human (H2H), and total cases for  
1727 each pathogen across the entire study region. (B) Annual number of vaccine campaigns that will  
1728 be triggered due to the outbreak threshold. (C) Number of vaccine regimens required per year  
1729 for outbreak response when either the general population or healthcare workers (HCWs) only  
1730 are targeted. (D) Annual number of cases averted via vaccination.